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Abstract
Intravenous tranexamic acid (TEA) is used in total hip arthroplasty (THA) to reduce
blood loss. Concern of increased thromboembolic risk has prompted the search for
treatment alternatives. The Tranexamic Acid Comparison in Hip Replacement (TeACHR) trial is a prospective randomized controlled trial comparing the efficacy of intravenous
and topical TEA in reducing perioperative blood loss. For interim data analysis, 52 of the
planned 144 participants had completed the initial phase of the TeACH-R trial. No
significant differences were identified between the intravenous and topical TEA
treatment arms for delta-hemoglobin (ΔHgb; 34.81±13.78 vs. 35.65±15.54 mg/dL;
p=0.840), calculated blood loss (1548±509 vs. 1521±693 mL; p=0.873), or length of stay
(55.0±11.44 vs. 54.5±20.1 hours; p=0.912). No participant required a blood transfusion
or had a thromboembolic event postoperatively. Promising initial results support the use
of topical TEA in THA, although therapeutic decisions should be made only once all data
has been analyzed.

Keywords
Orthopaedic Surgery, Blood Conservation, Tranexamic Acid, Blood Loss, Calculated
Blood Loss, Transfusion, Randomized Controlled Trial.
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1 Introduction

Blood conservation plays a very important role in the care of a patient with lower
extremity joint replacement. The procedure mandates consideration as major orthopaedic
surgery, where a significant amount of blood loss is expected both during and after
surgery. Tranexamic acid (TEA), a drug used to reduce perioperative blood loss, has
been touted as a valuable adjunct to many perioperative blood conservation protocols.
However, some concern remains over the efficacy and safety of the drug in hip
replacement surgery. This thesis will outline the development and results of a
prospective randomized clinical trial (RCT), the TeACH-R trial. The primary goal of this
trial is to assess the comparative efficacy of TEA administered via two distinct routes,
topical and intravenous, in decreasing blood loss after total hip arthroplasty (THA). The
following chapter outlines important clinical considerations leading to the development
of the TeACH-R trial.

1.1 Osteoarthritis
Osteoarthritis (OA) is characterized as progressive degenerative change resulting in
articular cartilage loss within a joint. Cartilage erosion results from altered joint motion.
In the lower extremity, the larger weight-bearing joints (the hip and knee) are affected
more often than the smaller joints of the foot and ankle. Osteoarthritis results in full
thickness, complete articular cartilage loss, with changes extending to the subchondral
bone. Reactive osteophytes and bony sclerosis cause symptoms of stiffness,
impingement and pain with weight bearing. Soft-tissue structures are also affected by
changes within the bony architecture. Chronic inflammatory changes within the
synovium cause hypertrophy, in addition to ligamentous laxity and muscle weakness
resultant from disuse and altered biomechanical forces within the joint.1
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The etiology of osteoarthritis is multifactorial, including both genetic and environmental
influences. Any joint in the body can be affected. A number of pathologic and anatomic
changes can lead to osteoarthritic changes. Although most commonly presenting in
idiopathic fashion without any identifiable cause (primary osteoarthritis), trauma,
osteonecrosis or congenital disorders are all secondary causes that can predictably lead to
degenerative changes. Typically, the disease presents in middle age, although it can be
earlier if secondary causes are suspected. Known risk factors for the development of hip
and knee osteoarthritis include advanced age, obesity, previous trauma or deformity in
the affected joint, and joint instability1. Pain and stiffness are the most frequent clinical
symptoms expressed by sufferers of the disease. Loss of active and passive range of
motion at the affected joint is the most relevant clinical sign. Radiographically, the
disease is defined by progressive joint space loss, often in association with osteophytosis,
sclerosis along the joint line, and subchondral cyst formation. The complete clinical
picture, in association with radiographic findings, determines the need for treatment.
A number of non-operative treatment options are available to the clinician treating
patients suffering with arthritis. Although the principles of osteoarthritis treatment are
generalizable to almost any joint, sufferers of lower extremity knee and hip osteoarthritis
deserve special consideration as weight-bearing joints. Conservative options attempt to
offload the affected joint, or compartment within the joint. These include activity
modification, weight loss, and functional bracing to compensate for altered force vectors
acting at the level of the joint. Furthermore, supplementing with non-invasive
pharmacologic agents helps in treating joint-related pain. Anti-inflammatories, including
non-steroidal anti-inflammatory drugs (NSAIDs) and acetaminophen, are mainstays in
the non-operative management of osteoarthritis with reliable therapeutic efficacy and
favorable side effect profile. Corticosteroid injections into the affected joint can also
provide a significant amount of pain relief. It is important, however, to realize that all
aforementioned treatment modalities are focused on management of pain-related
symptomatology. Although these help in delaying the need for operative intervention,
they do not halt the progression of disease. A high percentage of patients treated
conservatively for hip and knee osteoarthritis eventually progress to joint replacement
surgery due to incapacitating pain and disability unresponsive to conservative therapy. In
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Ontario, the burden of disease is significant: health care costs are 2 to 3 times higher, and
quality-of-life is consistently rated 10 to 25 percent lower in individuals with
osteoarthritis.2 Worldwide, it is estimated that 10 percent of all people over the age of 60
years suffer from OA. It has proven difficult to reliably assess the proportion of people
with OA who progress to THA, but there is evidence that the prevalence of OA does
increase with age3. With the aging population, the economic and social burden of
osteoarthritis is ever increasing.

1.2 Lower Extremity Arthroplasty
In the medical nomenclature, joint replacement surgery is termed arthroplasty: arthr(o)defined as “relating to a joint” and –plasty, of Greek origin “to form”4. Practically,
arthroplasty refers to the operative reconstruction or replacement of a diseased joint. The
term arthroplasty is all encompassing, often used to denote a variety of joint-related
reconstructive procedures. It is helpful to consider that all joints have two articulating
cartilaginous surfaces. Joint reconstruction implies resurfacing or replacing both
articulating surfaces of a joint. Often, like in THA, there is resection of supportive bone
mass along with the articular surface prior to implantation of the prosthesis.
Three bony articulations in the lower extremity are prone to degenerative changes
requiring reconstructive surgery: the ankle (tibio-talar) joint, the knee (tibio-femoral and
patellofemoral) joint and the hip (femoroacetabular) joint. Severe degenerative changes,
in association with debilitating symptoms and decreased quality of life, are indications
for joint replacement. The focus of this dissertation is on reconstruction of the hip joint.
The surgical procedure, as described in the following section, involves complete
resection of the femoral head and neck, with concomitant resurfacing of the acetabular
articular surface.

1.2.1 Total Hip Arthroplasty
Primary total hip arthroplasty continues to help a great number of individuals who suffer
from OA. The 2014 Canadian Joint Replacement Registry Annual Report states that
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24,515 primary total hip replacements were performed across Canada in 2012-135. As
can be seen in Figure 1.1, the vast majority of primary THA performed in Canada are for
a diagnosis of primary osteoarthritis.

Figure 1.1: Most Responsible Diagnosis for Primary Total Hip Replacement, fiscal
year 2012-2013. (Reproduced with permission from the Canadian Joint Replacement
Registry 2014 Annual Report, www.cihi.ca/cjrr)

Success of THA can be defined in many ways. From the patient perspective, satisfaction
is usually excellent after primary THA if the indication for surgery is for the relief of pain
associated with osteoarthritic changes within the joint. Quality of life reliably improves
after THA. From the standpoint of implant longevity, survivorship of most implant
systems is approximately 95% at 10-year follow-up6, 7. Overall, THA offers those with
end-stage degenerative hip disease a viable surgical option with predictably good
outcomes. However, it is considered a major intervention, putting the patient at risk both
during the procedure and throughout the postoperative course. Although the expected
benefits are significant, careful patient selection and preoperative medical optimization is
paramount in order to gain the most benefit with minimal risk.
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1.2.1.1

Surgical Technique

The modern age of THA comes after many fundamental changes in implant design and
materials engineering. However, the surgical technique remains similar to the lowfriction arthroplasty described by Sir John Charnley in the 19628, 9.
The bones of the hip joint lie deep in the area of the pelvis beneath a number of important
soft tissue structures, including muscles, tendons, nerves and arteries. There are many
described surgical approaches to exposing the femoral head and acetabulum safely. The
three main surgical approaches commonly used in North America are the modified direct
lateral (Hardinge) approach, the posterior (Southern-Moore) approach and the direct
anterior (Smith-Peterson or Heuter) approach. At London Health Sciences Center,
University Hospital (LHSC-UH), the most common approach is the modified direct
lateral approach. In his original publication, Dr. Kevin Hardinge describes the approach
with the patient laying supine on the operating table10; the modified Hardinge approach
uses lateral decubitus positioning to aid with visualization. Proponents of using this
approach cite adequate operative exposure, with a very low rate of prosthetic dislocation
of the implant in the postoperative period. Disadvantages are related to the transmuscular nature of the approach and limited visualization of the acetabulum.
Consequently, there is potential to increase surgical bleeding as a result of injury to the
perforating arteries located within the muscular layers of the upper thigh, as described in
Section 1.3.1.
Graphical representation of the modified Hardinge surgical approach to the hip joint is
outlined in Figure 1.2. Starting with a lateral skin incision centered over the greater
trochanter, sharp dissection proceeds through the subcutaneous fat layer to reveal the
fascia of the gluteal musculature, thickening distally to form the iliotibial (IT) band. A
longitudinal incision through the IT band and fascia allows identification of the gluteus
medius musculature overlying the anterolateral aspect of the proximal femur. In the next
tissue layer, a split in the gluteus medius muscle belly in line with its muscle fibers
overlying the femoral neck allows identification of gluteus minimus. An incision is made
through the tendinous portion of gluteus minimus and the capsule overlying the femoral
neck. Reflection of the gluteus medius and vastus lateralis off the anterior aspect of the
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femur allows visualization of the entire proximal femur. After release of periarticular
structures, surgical dislocation of the femoral head allows enough visualization to
properly landmark the femoral neck osteotomy site approximately one centimeter above
the lesser trochanter. Once the osteotomy is completed, the femoral head is excised and
the shaft of the proximal femur translated posterolaterally. The floor of the acetabulum is
then visible, and preparation of the femoral and acetabular surfaces for implantation of
the prosthesis can proceed.

A

B

C

D

Figure 1.2: Modified Direct Lateral (Hardinge) Approach to the Hip Joint. After the
skin incision, an incision is made through the IT band and gluteal fascia (A). The gluteus
medius is divided, leaving a tendinous cuff attachment to the greater trochanter (B),
exposing the gluteus minimus and capsular tissue layers (C). Further incision through the
gluteus minimus and capsule, followed by elevation of a muscular flap off the anterior
proximal femur, allows dislocation of the femoral head and preparation for the femoral
neck osteotomy (D). (Reproduced with permission and copyright © of the British
Editorial Society of Bone and Joint Surgery from Hardinge, K. J Bone Joint Surg Br
1982; 64-B(1): 17-19)
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Although cement fixation of femoral and acetabular components was common practice in
the past, and still has a role in primary THA for hosts with poor capacity for bony
ingrowth, cementless (press-fit) fixation is the popular choice for the majority of North
American surgeons. The sequence of preparation of the femoral neck osteotomy and
acetabular surfaces for implantation of cementless implants is surgeon-dependent. For
the acetabulum, all soft tissues, including the labrum, are excised to reveal the entire
articular surface. Reaming of the acetabulum, a process of excising degenerative
acetabular cartilage and sclerotic bone using sequential reamers of increasing diameter,
allows the creation of a bed and surrounding rim for fixation of the press-fit shell. This
shell will hold a highly cross-linked polyethylene liner, the acetabular bearing surface.
On the femoral side, the intramedullary canal is first identified, and preparation of the
canal allows for sizing of the final prosthesis. Rotational and axial stability of the
femoral implant is due to a secure fit of the prosthesis within the proximal femur.
Modern implants have a modular femoral head component sitting on the femoral stem at
the head-neck junction. Trialing of various femoral head lengths allows for appropriate
sizing. This critical step is necessary in order to maintain appropriate implant stability,
keeping in mind the patient’s soft tissue tension and leg length. Once the final
components are selected, implantation ensues, with subsequent closure of all tissue layers
to complete the operative procedure.
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Figure 1.3: Modern Cementless Total Hip Implant (in situ). The femoral component
is press-fit into the proximal metadiaphyseal portion of the intramedullary canal. The
modular femoral head component articulates with the liner. The acetabular shell is firmly
seated into the reamed acetabulum. (Reproduced with permission and copyright © from
Pivec, R et al. Lancet 2012; 380: 1768-77)

1.3 Blood Loss During and After Total Hip Arthroplasty
Despite the best intentions of the treating orthopaedic surgeon, complications are
occasionally seen after THA. Clinically significant blood loss often presents insidiously.
The soft tissues in and around the hip, notably the significant adiposity in the subdermal
layers of the thigh, make the THA patient vulnerable to a significant amount of
unrecognized blood loss during and after the operative procedure. Unlike in total knee
arthroplasty (TKA), a tourniquet cannot be applied prior the operation given the proximal
nature of the skin incision. Best efforts to maintain intraoperative hemostasis are taken
by the treating surgeon and anesthesiologist, in order to reduce bleeding into the
postoperative period.

1.3.1 Sources of Blood Loss During Total Hip Arthroplasty
Importantly, bone ends that have been osteotomized have a propensity for continued
bleeding into the postoperative period. Unfortunately, the surgeon has limited options for
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dealing with bleeding from vessels contained within bone, as neither electro-cautery nor
suture ligation is effective at arresting the persistent ooze emanating from cancellous
bone. Both the femoral intramedullary canal and the periacetabular region contain a
significant amount of cancellous bone. In THA, bony blood loss arises from both the
femoral neck osteotomy site and subchondral bone on the acetabular surface after the
latter has been reamed. Although implantation of final components in press-fit fashion
does provide a mechanism for local tamponade of bleeding bone, in the absence of a
competent clotting cascade continued hemorrhage may be significant enough to require
transfusion of packed red blood cells, either autogenic or allogeneic. Moreover, the
direct lateral approach, trans-muscular by definition, does place the perforating
intramuscular branches of the femoral arterial system at risk of injury. Ruptured
intramuscular arteries can retract into the muscle bed, making it particularly difficult to
grasp and ligate the ends of the injured vessel intraoperatively. The above can occur
without any overt external blood loss or hematoma formed in the visible superficial
tissues surrounding the hip joint. It is this slower, persistent bleeding that is targeted with
the administration of antifibrinolytic agents in the perioperative period, as described in
Section 1.4 and 1.5.
Thankfully, vascular injury to the main branches of the iliac, femoral or obturator
vascular system remains a rare complication of THA, estimated at 0.25%11, usually as a
result of aggressive retractor placement in the antero-superior acetabulum and proximal
femur. The placement of acetabular screws is also a risk factor for intraoperative
bleeding given the relative proximity to major blood vessels, as seen in Figure 1.5. Deep
drill or screw penetration can lead to vascular penetration, thrombosis, and significant
amounts of intra-pelvic blood loss. Although rare, this does represent another source of
blood loss in THA. Antifibrinolytics do not target these causes of massive intraoperative
hemorrhage.
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A

B
Figure 1.4: Common Femoral Artery and Major Branches Around the Hip.
Proximal (A) and distal (B) extension of the external iliac and common femoral artery is
visualized above. Important anatomic relationships of relevance to the surgical approach
for the hip are noted. The smaller branches of the femoral arterial system are at risk
during the direct lateral surgical approach. (Reproduced from Nachbur, B et al. CORR
1979; 141: 122-132)
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Posterior

Anterior

Figure 1.5: Relationship of Pelvic Vascular Structures to Surface Acetabular
Landmarks. For acetabular screw placement, the “safe zone” corresponds to the
postero-superior quadrant of the acetabulum, where the only vascular risk is the superior
gluteal artery. “Danger zones” correspond to the antero-superior and antero-inferior
quadrants, where the external iliac vessels and obturator pedicle lie in close proximity to
the acetabular fossa. (Reproduced with permission and copyright © from Springer,
Feugier, P et al. Surg Radiol Anat 1997; 19(2): 85-90)

1.3.2 Physiologic Response to Surgical Blood Loss
The human response to blood loss is predictable. If hypovolemia due to hemorrhage is
significant, the initial response is to maintain cardiac output. Until hypovolemia is
corrected, a decrease in cardiac preload results in a decrease in stroke volume. Heart rate
increases proportionally to compensate for the lack of intravascular volume, and systemic
vascular resistance decreases to reduce cardiac afterload. Although transport of oxygen
is presumed to be negatively affected by an acute loss of red blood cell mass, Weiskopf et
al showed that in healthy conscious volunteers at rest, a drop in hemoglobin to 50 mg/dL
did not result in a significant drop in oxygen carrying capacity or clinically significant
tissue hypoxia12. Although these represent important findings, the stress of major

12

orthopaedic surgery in the elderly arthroplasty patient is likely to produce significant
biochemical changes affecting that individual’s physiologic capacity to respond to acute
or subacute blood loss.
The coagulation and fibrinolytic systems are the keystones of the human body’s inherent
hemostatic mechanism. Both pathways are termed cascades because of the hierarchical
activation of serine proteases. One receptor-ligand interaction triggers a coordinated set
of downstream reactions, eventually leading to a stable clot. The dynamic interplay
between coagulation and fibrinolysis attempts to seal a bleeding vessel, while
maintaining enough patency of the vascular lumen to allow nutrient delivery to
downstream tissues. Coagulation, as the name implies, performs the former function and
occurs by interacting closely with the initial platelet plug to form a stable complex of
macromolecules, or clot, over bleeding vessels. Fibrin, the active form of the pro-peptide
fibrinogen, plays an important role in the process of coagulation, forming an intricate
network of cross-linked fibers within the platelet plug to form an insoluble clot. On the
other hand, fibrinolysis acts to break down this clot in order to maintain a patent
intravascular lumen. Here, plasmin plays a key role in breaking apart the cross-linked
fibrin. These cascades are outlined in Figure 1.6.
Although the intrinsic pathway is an important contributor to coagulation, the extrinsic,
or tissue factor-mediated coagulation pathway is predominantly responsible for the
initiation and propagation of the coagulation cascade during and after surgical trauma.
Tissue factor (TF), a macromolecule present in the subendothelial layer of blood vessels
and in the extracellular environment, is not exposed to flowing blood unless there is
vascular injury causing intimal damage. TF is the receptor for factor VII (FVII), the
latter flowing freely in the bloodstream. FVII interact with TF only if TF becomes
exposed to flowing blood; upon binding, FVII becomes activated (FVIIa), and
subsequently interacts with factor X (FX). FX, once activated, cleaves prothrombin to
thrombin. Thrombin, in turn, cleaves fibrinogen to fibrin, the active monomer
contributing to a highly cross-linked mesh able to stabilize the initial platelet plug.
Thrombin also catalyzes the conversion of factor XIII (FXIII) to its active form (FXIIIa),
which is a necessary cofactor for cross-linking of fibrin monomers13.
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Figure 1.6: Overview of the Coagulation and Fibrinolytic Cascades. Tissue Factor is
released when a blood vessel is injured. The subsequent cascade of serine proteases leads
to the conversion of prothrombin to thrombin, which converts fibrinogen to fibrin. Under
the influence of Factor XIIIa, fibrin monomers get cross-linked. Fibrinolysis occurs upon
binding of tissue plasminogen activator (tPA) to plasminogen, with subsequent
conversion to plasmin. Plasmin then degrades the fibrin clot, with formation of fibrin
degradation products. (Reproduced from McGilvray, ID and Rotstein, OD. Surgical
Treatment: Evidence-Based and Problem-Oriented. 2001.
http://www.ncbi.nlm.nih.gov/books/NBK6959/)

Fibrinolysis is the counter-regulatory process that assures continued flow through the
lumen of the bleeding vessel. Plasminogen is the inactive precursor of plasmin,
circulating in the bloodstream. Conversion of plasminogen to its active form proceeds
only once plasminogen binds to fibrin, where this zymogen adopts an open conformation.
Only at this point is an activator, such as tissue plasminogen activator (tPA), able to bind
the molecule and convert it to its active serine protease, plasmin. Plasmin can then act to
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cleave the fibrin cross-links, destabilizing the formed clot in order to ensure vessel
patency14. Fibrin degradation products (FDP) are formed upon cleavage of fibrin crosslinks.

1.3.3

Hemostasis in Arthroplasty

Total knee and total hip arthroplasty produce a significant amount of tissue trauma. In
TKA, postoperative hemostasis is largely influenced by the accelerated fibrinolytic
reaction at time of tourniquet release15, 16. The same is not seen in THA, as tourniquet
application is not possible when operating on the hip joint. Initiation of the coagulation
cascade, with concurrent activation of the fibrinolytic system, begins from the time of
initial of tissue trauma. The surgeon is dependent on a number of surgical techniques to
control blood loss in the surgical field during THA. Suture ligation, electro-cautery and
the application of synthetic sealant products and tissue glues are valuable tools available
to the surgeon attempting to achieve intraoperative hemostasis. Watertight closure
techniques with the concomitant goal of decreasing dead space between tissue layers can
also decrease the space available for collection of blood in the potential spaces around the
hip joint. The anaesthesia team has a key role in identifying and treating surgical
hypovolemia. The administration of intravenous resuscitative fluids, vasoactive
medications and the control of blood pressure contribute significantly to reducing
intraoperative blood loss. However, as mentioned in Section 1.3.1, not all sources of
intra-operative blood loss are amenable to correction via these modalities.
Bleeding in the postoperative period is further potentiated by the need for anticoagulation
after lower extremity total joint arthroplasty. Total hip and knee arthroplasty are
considered procedures that carry a moderate-to-high risk of postoperative
thromboembolic events. A deep vein thrombus (DVT) can migrate proximally
throughout the venous system to cause pulmonary emboli (PE), both considered major
venous thromboembolic events (VTE). If large enough in size, PEs can lodge in the
pulmonary arterial tree, resulting in a ventilation-perfusion mismatch. If the area of lung
affected is large, or in the event of the dreaded saddle embolus blocking the confluence of
the right and left pulmonary arteries, this can be a fatal complication of elective surgery.
Commonly, a direct thrombin inhibitor such as rixaroxaban, or an agent in the low-
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molecular-weight heparin class such as dalteparin is indicated for the purpose of
decreasing the incidence of these important, potentially life-threatening postoperative
complications. In respective guideline statements, the American College of Chest
Physicians and the American Academy of Orthopaedic Surgeons both strongly endorse
thromboembolic prophylaxis as standard of care after lower extremity total joint
arthroplasty17, 18. In a recent randomized clinical trial published in the New England
Journal of Medicine, major VTE occurred in only 0.2% of 1595 participants receiving
rivaroxaban, an absolute risk reduction of 1.7% when compared to the treatment group
receiving enoxaparin, another oft-utilized thromboprophylactic agent19. On the other
hand, the incidence of asymptomatic DVT or PE is estimated at approximately 50% when
prophylactic anticoagulation is not initiated in the postoperative period20. The contrasting
results of these studies emphasize the need for effective thromboprophylaxis after THA.
Management of blood loss in arthroplasty is a significant challenge, not only because of
difficulties in controlling the source of blood loss, but also because of a lack of
therapeutic options in modulating the coagulation and fibrinolytic cascades to effectively
decrease blood loss. In attempts to stop bleeding, maintaining vessel patency and
avoidance of dreaded thromboembolic complications are also critical factors to consider
in the perioperative care of the arthroplasty patient. Blood conservation protocols reflect
these goals of treatment.

1.4 Perioperative Blood Conservation
1.4.1 Preoperative Anemia in the Total Hip Arthroplasty Patient
The adverse effects of blood loss are complicated by the relatively high incidence of
preoperative anemia in the arthroplasty patient population. It is estimated that
approximately 25 to 45 percent of patients proceeding to THA or TKA are anemic preoperatively21. Preoperative use of NSAIDs causing subacute gastrointestinal blood loss
and anemia of chronic disease are prevalent etiologies for anemia in the arthroplasty
patient. Preoperative anemia has been cited as a risk factor for postoperative infection,
transfusion, and even mortality21. In a landmark paper, Carson determined that “the
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effect of blood loss on mortality was larger in patients with low preoperative hemoglobin
than in those with a higher preoperative hemoglobin.”22
The presence of concurrent medical comorbidities mandates a thorough preoperative
medical review as a part of the evaluation of the perioperative evaluation for the
arthroplasty patient. Management of preoperative anemia, in particular, plays a large role
in medical optimization prior to total joint arthroplasty. As mentioned in Section 1.3.2,
decreased oxygen carrying capacity from low red blood cell mass decreases the potential
for aerobic metabolism in downstream tissues, increasing the risk for end-organ ischemia.
Although this may not be a factor in young, healthy individuals, the typical elderly
arthroplasty patient does not meet these criteria. The heart is particularly vulnerable in
this patient population. The presence of ischemic heart disease, in addition to concurrent
pharmacologic treatment with cardiogenic medications, decreases the intrinsic
physiologic response to surgical stress.

1.4.2 Risk of Perioperative Transfusion
It is now understood that allogeneic transfusion for the treatment of anemia related to
surgical blood loss should be avoided when possible. In addition to cost and resource
constraints, the current evidence shows an increased risk of surgical site, urinary tract and
respiratory tract infections in patients that receive allogeneic blood in the postoperative
period23-26. Ongoing concerns regarding the safety of transfusing stored blood products
have ushered in the use of restrictive transfusion algorithms for surgical patients, showing
significant clinical benefit over the liberal transfusion of blood products in a number of
high-quality studies in surgical and critically ill patients22, 27, 28. A restrictive transfusion
algorithm is in use at LHSC-UH; further details are provided in Chapter 3.5.3.

1.4.3 Blood Conservation Modalities
A multidisciplinary approach to blood conservation in total joint arthroplasty is
paramount to optimal perioperative care of the arthroplasty patient. Although there exists
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some heterogeneity in blood conservation protocols across centers, several common
themes are present.
Pharmacologic iron supplementation and the use of erythropoietin-stimulating agents
(ESA) increase red cell mass prior to surgical intervention, with good efficacy and
reasonable safety profiles21. Both can have significant clinical benefits, especially if
started over 3 weeks prior to surgery29. Whereas iron supplementation has proven benefit
with general ease of administration preoperatively, ESA can be a costly modality
reserved for patients meeting strict diagnostic criteria. Preoperative autologous blood
transfusion, intraoperative cell salvage, and postoperative blood reinfusion strategies are
moderately effective, and have been used as part of perioperative blood conservation
protocols in the past. However, these have decreased in popularity as a result of
modalities that are less resource-intensive and of similar efficacy and safety30, 31. A
number of studies in both hip and knee arthroplasty have affirmed the clinical utility of
antifibrinolytic agents, such as TEA, in reducing blood loss in the perioperative period.
As evidenced in the following sections, these represent promising adjuncts to traditional
blood conservation protocols, especially for the patient at risk of significant
intraoperative blood loss.

1.5 Antifibrinolytics
The use of antifibrinolytic therapy in surgery has grown due to a number of inciting
factors and events. In recent years, the ever-increasing cost and incidence of transfusionrelated complications has ushered in widespread reluctance to the use of blood products
in the perioperative setting. Consequently, medical and surgical teams managing of the
perioperative care of patients having surgical interventions with an elevated risk of blood
loss have developed blood conservation protocols to decrease the reliance on allogeneic
blood products for the treatment of surgical anemia. Antifibrinolytics, such as TEA,
epsilon-aminocaproic acid (EACA) and aprotinin, were first identified as useful adjuncts
in cardiothoracic interventions, where a counter to the potent fibrinolysis-inducing effect
of cardiopulmonary bypass was sought by surgeons and anaesthesiologists seeking better
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control of perioperative bleeding. After a number of high-quality studies showed good
clinical effect with minimal risk to the patient32-34, orthopaedic surgeons began to
institute antifibrinolytics prior to and during procedures carrying a significant risk of
blood loss, lower extremity total joint arthroplasty included. The following section
provides an overview of the pharmacology inherent to antifibrinolytic therapy, and its
role in the perioperative care of the arthroplasty patient.

1.5.1

Lysine Analogues: Tranexamic Acid and EpsilonAminocaproic Acid

Tranexamic acid and epsilon-aminocaproic acid comprise the lysine analogue class of
antifibrinolytic agents. They have identical mechanisms of action, with TEA displaying a
six- to ten-fold increased affinity compared to the EACA moiety35, 36. Owing to its high
affinity and comparatively low cost, TEA has largely replaced EACA as the predominant
lysine analogue used in major orthopaedic procedures.
Lysine analogues prevent fibrinolysis. The structural similarity to the amino acid lysine
allows the drug to bind the lysine-binding site on plasminogen. Under normal
circumstances, plasminogen is a promoter of fibrinolysis when combined with tPA.
Plasminogen subsequently gets converted to plasmin, with the active lysine-binding site
on plasmin now able to interact with the active receptor on fibrin. Plasmin can then
break down cross-linked fibrin and dissolve insoluble mesh of fibrin holding the clot
together. TEA acts as a competitive inhibitor of plasminogen via action at this fibrinbinding site. Plasmin can no longer bind fibrin when TEA is bound to the lysine-binding
site. Fibrin remains cross-linked, stabilizing the formed clot and promoting local
hemostasis (Figure 1.7).
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Figure 1.7: Mechanism of Action, Tranexamic Acid (and Epsilon-Aminocaproic
Acid). Due to structural similarities to lysine, both tranexamic acid and epsilonaminocaproic acid moieties competitively inhibit binding of fibrin to plasminogen via
interaction at an active lysine-binding site. Fibrinolysis is prevented, with concomitant
stabilization of the fibrin clot. (Reproduced with permission from Dunn, CJ and Goa,
KL. Drugs 1999; 57: 1005-1032)

The pharmacokinetic properties of the lysine analogues make this class of medication
ideal for decreasing the short-lived intra-articular fibrinolytic response after lower
extremity joint replacement surgery. Both molecules rapidly diffuse across tissue planes,
and are able to reach effective concentrations within the joint shortly after intravenous
administration. Studies in cardiac surgery have elucidated the pharmacokinetic and
pharmacodynamic properties of intravenous TEA, sought after in attempts to find the
safest and most effective dose. It has been determined that the distribution and
elimination of TEA follows first-order kinetics, with a half-life of roughly 2 hours. TEA
is not bound to proteins in the systemic circulation, and is rapidly excreted in urine
largely unchanged in chemical structure. A serum concentration of 10-15 µg/mL
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decreases fibrinolytic activity of plasmin by approximately 80%38. Also, when
administered via the topical or intra-articular routes, systemic absorption of TEA is
reduced by approximately 70% of the equivalent intravenous dose39. Because of renal
elimination, dose adjustments are necessary in those with decreased kidney function, but
not in those with hepatic impairment35, 36. Other side effects, as well as local and
systemic allergic reactions are rare complications of antifibrinolytic administration.

1.5.2

Plasmin Inhibitors: Aprotinin

Aprotinin, a thrombin inhibitor derived from bovine lung tissue, has also been in total
joint arthroplasty. Its activity on the fibrinolytic cascade has yet to be fully elucidated,
although it is postulated to exert most of its clinical effect indirectly by decreasing the
activation of factor XII through an inhibitory effect on the kallikrein pathway. The
proteolytic activity of plasmin is also inhibited by aprotinin directly, although the
mechanism is unclear40.
In 2008, use of aprotinin was restricted in a number of countries, including both Canada
and the United States, as a result of increased mortality when used in cardiac surgery.
These results emanated from a large multi-center study, the Blood Conservation using
Antifibrinolytics in a Randomized Trial (BART)41. These same findings were not present
when TEA was used for this same purpose. Within the past two calendar years, the
European Medicines Agency and Health Canada have reinstated aprotinin for use in
cardiac surgery, but only in cases where an excessive amount of blood loss is expected.
Given the increased cost as well as safety concerns related to use of aprotinin, it is no
longer routinely used as an antifibrinolytic agent in orthopaedic surgery.

1.6 Tranexamic Acid Administration in Total Hip Arthroplasty
TEA is a versatile drug that has been used with therapeutic success in bleeding trauma
patients42, gynecologic surgery, cardiac surgery43, 44, 33, 45, thoracic surgery34 and only
more recently orthopaedic surgery. Administration via the oral, topical, intra-articular
and intravenous routes is described in each of these surgical fields. As will be discussed
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in Chapter 2, there is documented Level I evidence to support the use of TEA in both
TKA and THA. Although these procedures are inherently different in many ways, a
review of the available evidence in TKA is essential to understand the rationale in the
TeACH-R study design and the need to assess the clinical efficacy for intra-articular
administration of TEA in THA.
The comparative efficacy of intravenous and topical administration of TEA has never
been assessed in patients undergoing THA. TeACH-R is the short form for the study
entitled Tranexamic Acid Comparison in Total Hip Replacement, a study developed at
LHSC-UH powered to detect a clinically significant change in the hemoglobin drop after
THA. The purpose of the study is to perform a direct comparison of clinical efficacy
between intravenous and topical administration of TEA, with the primary outcome
measure of blood loss and drop in postoperative hemoglobin. The standard of care at
LHSC-UH, based predominantly on results of a 2010 retrospective review by Ralley and
colleagues, is to administer a single dose of 20 mg/kg of TEA intravenously 10 minutes
prior to skin incision for THA46. This allows the solution to be infused completely before
the start of the operation. The drop in hemoglobin postoperatively was lessened, with a
concomitant decrease in the rate of postoperative allogeneic blood transfusion. However,
an important study by Wong suggests that topical TEA administration in TKA has similar
clinical benefit in terms of decreased blood loss and transfusion rate, with either a 1.5
gram or 3 gram single-bolus dose administered prior to tourniquet desufflation. In this
study, plasma TEA levels drawn one hour after administration showed sub-therapeutic
levels in the group receiving the 1.5 gram dose, indicating that even marginal plasma
TEA levels can have good therapeutic effect in inhibiting the local fibrinolytic cascade
without the risk that comes with elevated systemic load. To the best of the investigators’
knowledge, a similar study has yet to be performed in THA, owing in large part to the
lack of consistency in dosing and timing of administration in published studies examining
TEA.
Direct antifibrinolytic action on bleeding vessels and a decreased risk of arthroplastyrelated thromboembolic events (albeit theoretical) are potential advantages of
administering TEA topically in THA. The TeACH-R investigators decided to administer
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TEA topically at the time of arthrotomy closure, as it provides a reproducible method of
administering the medication without interfering with surgical time while maintaining
therapeutic activity. The goal is to target postoperative blood loss from intramuscular
vessels and cancellous bone, in order to blunt the hemoglobin drop and reduce the need
for transfusion of pRBCs. By allowing the TEA solution to bathe the joint while the
tissue layers are closed in succession, the drug is then given a significant of time to exert
its clinical action. A dose of 1.5 grams was chosen based on the results of previous
studies showing no clinical benefit of a higher dose in total joint arthroplasty39. Blood
loss and complications in TeACH-R study participants receiving this topical regimen are
compared to single-bolus intravenous TEA administration at 20 mg/kg, the standard of
care at LHSC-UH. Because the standard of care is an active agent with well-documented
clinical efficacy, a placebo-controlled trial in this setting has significant ethical
implications.
We hypothesize that administering topical TEA at the time of arthrotomy closure will not
show a significant drop in the postoperative hemoglobin or perioperative blood loss when
compared to intravenous TEA administered prior to the start of THA.
There is a significant body of evidence supporting the use of TEA over no antifibrinolytic
therapy, whether it is administered intravenously or topically47. Proceeding with this
study is part of the process of determining which is the most effective therapeutic
regimen for administering TEA in THA. Not only will our results go a long way in
optimizing blood conservation protocols for patients proceeding to THA at LHSC-UH,
but this study will also allow others in the field to build on the current available
knowledge base in order to gain the most clinical benefit of TEA while minimizing
perioperative risk.
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2 Literature Review

The following provides a brief overview of the relevant studies that have contributed to
the gradual increase in popularity of TEA as a valuable adjunct in perioperative blood
conservation programs. Only recently have appropriately powered clinical trials
demonstrated clear benefit of administering TEA in both TKA and THA, regardless of
whether the route of administration is intravenous (IV), intra-articular (IA) or topical.

2.1 Intravenous Tranexamic Acid in Total Knee Arthroplasty
Evidence supporting the use of TEA in lower extremity total joint arthroplasty first
appeared in a small series of patients needing TKA, where Benoni et al showed that TEA
would provide an effective counter to the hyperfibrinolytic reaction seen after tourniquet
desufflation in TKA15. Ease of use and ability to administer serial doses of TEA were
seen as advantages to administering the drug intravenously, although early reluctance to
implementing TEA came from clinical studies that questioned the earlier claims of
efficacy in decreasing blood loss after knee replacement surgery. Good et al assessed the
effect of TEA on hidden blood loss in TKA using a 10 mg/kg dose of IV TEA given just
before tourniquet release, concluding that the hemostatic agent reduced total blood loss
and drain volume, but showed no discernable effect on reduction of hidden blood loss48.
Larger, more recent studies have shown more promising results. A European clinical
trial provided Level I evidence supporting the clinical and economical benefits of IV
TEA in TKA, stating that use of TEA in the perioperative setting reduced blood loss by
approximately 600 mL compared to placebo, making postoperative autologous reinfusion
unnecessary and cost-prohibitive when a restrictive transfusion protocol is enforced
concurrently30. In comparison to other traditional methods of intraoperative blood
conservation, when two separate formulations of fibrin glue were compared to IV
administration of TEA in a recent clinical trial, TEA was deemed to be the only effective
agent in decreasing drain and calculated blood loss49.
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Although a general consensus exists supporting the benefits of IV TEA in TKA,
significant heterogeneity exists between studies with regards to treatment regimens and
outcome measures, making it difficult to reliably assess the true clinical effect of
adjunctive antifibrinolytic therapy. The ideal protocol with regards to dosing and timing
of administration has yet to be fully elucidated, although recent evidence suggests
improved control of postoperative blood loss with serial administration of TEA during
the perioperative period. In order to clarify this conflicting data, Maniar and colleagues
designed a trial comparing four separate modes of TEA administration. In their study,
patients receiving preoperative, intraoperative and postoperative administration of IV
TEA at 10 mg/kg/dose had the least drain output and total blood loss compared to the
group who received either one or two doses of the drug perioperatively, suggesting that
serial dosing allows for optimal perioperative efficacy50. A prospective study by Alvarez
et al also showed that a cohort of TKA patients receiving IV TEA as a bolus prior to
tourniquet release supplemented by a 1 mg/hr infusion for 6 hours postoperatively had
significantly decreased levels of drain and total calculated blood loss. In this study, the
quoted number needed to treat to avoid one unit of blood transfused (autologous or
allogeneic) is 9.2, further highlighting the efficacy of IV TEA in decreasing blood loss
and rate of transfusion for patients having TKA51.
Logistical barriers do, however, make timed serial dosing strategies and continuous bolus
infusion difficult to administer, especially as the arthroplasty patient transitions to the
postoperative recovery phase. There are single-bolus regimens that have shown to be
safe effective and safe. A large-scale retrospective review of TKA cases performed
before and after the implementation of a perioperative TEA protocol, consisting of a
single IV TEA dose of 20 mg/kg prior to tourniquet release, showed significant
reductions in hemoglobin drop and blood transfusion rates postoperatively46. The higher
dose used in this protocol, much like other studies of relevance, did not show any
clinically significant increase in thromboembolic complications.
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2.2 Topical Tranexamic Acid in Total Knee Arthroplasty
There is also Level I evidence to support the use of topical TEA for reduction of blood
loss after TKA. A recent clinical trial showed equivalent efficacy of a 1.5 and 3-gram
topical TEA solution in reducing calculated blood loss by factor of approximately 25%
compared to placebo39. In this study, a valuable addition to the clinical trial protocol is
the biochemical analysis of plasma levels of TEA, measured one hour after
administration in all treatment groups. The 1.5-gram topical dose resulted in significantly
lower systemic load than the group receiving the higher dose, with no differences in the
desired clinical effect. In a further attempt to contrast the effect of the different routes of
administration on postoperative blood loss, Seo and colleagues published results of their
three-armed prospective cohort study demonstrating modest improvements in hemostasis
and drain output in the treatment arm receiving IA TEA, when compared to both IV TEA
and placebo52. Although the latter group was only administered IV TEA after the
surgical site was closed, this study provides further evidence in support of IA or topical
administration of TEA in TKA. A review of recent studies examining the use of TEA in
TKA is presented in Table 2.1.
Table 2.1: Selected Studies Evaluating the Use of Tranexamic Acid in Total Knee
Arthroplasty.
Treatment Arms
Good et al (2003)

Blood Loss

Transfusion

Complications

TEA < placebo

TEA = placebo

48

1. IV TEA bolus 10 mg/kg at
tourniquet release + repeat 10
mg/kg bolus 3 hours later; n=27.
2. Placebo; n=24

TEA < placebo
(total)
TEA = placebo
(hidden)

Alvarez et al (2008)51
TEA < placebo
(alloRBC)

1. IV TEA 1 gram bolus at
tourniquet release + 1 mg/kg/hr
infusion for 6 hours postop; n=46
2. Placebo; n=49

TEA < placebo

Ralley et al (2010)46
1. IV TEA bolus 20 mg/kg bolus at
incision; n=150
2. Placebo; n=145
Wong et al (2010)39

TEA < placebo

TEA < placebo
(autoRBC)

TEA < placebo

NR

TEA = placebo
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Treatment Arms

Blood Loss

Transfusion

Complications

0. Placebo; n=35
T1. Topical TEA 1.5 grams at
closure; n=31
T2. Topical TEA 3 grams at
closure; n=33

T1 < placebo
TEA = placebo

TEA = placebo

TEA < placebo

TEA = placebo

TEA = placebo

TEA = placebo

IA < placebo

IA < placebo

IA = IV

IV < placebo

IV < placebo

IA = placebo

IA < IV

IA = IV

IV = placebo

TEA < placebo

TEA < fibrin

TEA < fibrin

fibrin = placebo

T2 < placebo
T1 = T2

Charoencholvanich and Siriwattanasakul (2011)53
1. IV TEA 10 mg/kg pretourniquet inflation + repeat 10
mg/kg bolus 3 hours postop + 500
TEA < placebo
mg TID orally x 5 days postop;
n=50
2. Placebo; n=50
Maniar et al (2012)50
0. Placebo; n=40
T1. IV TEA bolus 10 mg/kg at
tourniquet release; n=41
T2. IV TEA bolus 10 mg/kg at
tourniquet release + repeat 10
mg/kg bolus 3 hours postop; n=42
LA < T1
T3. IV TEA bolus 10 mg/kg prior
to tourniquet inflation + repeat 10
T3 < placebo
mg/kg bolus at tourniquet release;
n=42
T4 < placebo
T4. IV TEA bolus 10 mg/kg prior
to tourniquet inflation + repeat 10
LA < placebo
mg/kg bolus at tourniquet release +
repeat 10 mg/kg bolus 3 hours
postop; n=41
LA. Topical TEA 3 grams at
closure; n=41
Seo et al (2012)52
1. IA TEA 1.5 grams at closure;
n=50
2. IV TEA bolus 1.5 grams at
closure; n=50
3. Placebo; n=50
Aguilera et al (2013)49
1. BSTC Fibrin Glue; n=42
2. Tissucol; n=41
3. IV TEA bolus 1 gram x 2, first
dose prior to tourniquet inflation,
second dose prior to tourniquet
release; n=41
4. Placebo; n=42
Georgiadis et al (2013)54

TEA = fibrin =
placebo
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Treatment Arms
1. Topical TEA 2 grams at closure;
n=50
2. Placebo; n=51
Konig et al (2013)55
1. IA TEA 3 grams at closure;
n=130
2. Placebo; n=29
Alshryda et al (TRANX-K; 2013)56
1. Topical TEA 1 gram at closure;
n=79
2. Placebo; n=78
Oremus et al (2014)30
1. IV TEA bolus 1 gram at incision
+ repeat 1 gram bolus 3 hours later;
n=29
2. Placebo; n=27

Blood Loss

Transfusion

Complications

TEA < placebo

TEA < placebo

TEA = placebo

TEA < placebo

TEA < placebo

NR

TEA < placebo

TEA < placebo

TEA = placebo

TEA < placebo
(intraoperative)

IV TEA <
placebo
(autoRBC)

TEA = placebo
IV TEA =
placebo
(alloRBC)
*IV: Intravenous TEA. IA: Intra-Articular TEA. AutoRBC: Autologous Blood Reinfusion.
AlloRBC: Allogeneic Blood Transfusion. “<”: Less than. “=”: Equal to. NR: Not Reported.
TEA < placebo
(drain loss)

2.3 Intravenous Tranexamic Acid in Total Hip Arthroplasty
Like in TKA, IV TEA has been shown to be effective, safe, and relatively easy to
administer to patients undergoing primary THA. Appropriate timing of IV TEA
administration is paramount. One of the first studies on the subject was a small doubleblinded trial by Benoni, concluding no benefit with regards to blood loss when the drug
was infused after implantation of the prosthesis57. A similar placebo-controlled study
demonstrated that IV TEA administered prior to the start of the procedure showed
significant benefit for both intra- and postoperative blood loss in the treatment group58.
Although the sample size in these clinical trials is small, the contrasting results highlight
the importance of appropriate timing of administration.
Variation also exists in the published protocols for IV administration of TEA during
THA. There does not appear to be strong benefit of either a single-dose or multi-dose
regimen when the drug is used in hip surgery. A retrospective review of five separate
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regimens of IV TEA in THA showed benefit in decreasing drain output when
administering the drug prior to skin incision with a repeat bolus dose 6 hours later59. In
contrast, a study published in 2005 by Johansson demonstrated that a single dose of 15
mg/kg, given at the start of the procedure, is effective in decreasing calculated blood loss
and the need for transfusion in the postoperative period60. Similarly, at our institution,
we demonstrated a significant benefit with regards to decreased rate of transfusion when
a single bolus dose of 20 mg/kg given prior to skin incision was used in THA. In this
latter study, the postoperative drop in hemoglobin was attenuated in the cohort of patients
having received IV TEA, in addition to an observed decrease in the rate of postoperative
allogeneic blood transfusion46.

2.4 Topical Tranexamic Acid in Total Hip Arthroplasty
Although limited, evidence supporting the use of topical TEA in THA continues to grow.
Preliminary evidence emanating from a randomized controlled trial by Konig et al
demonstrates that a protocol of topical TEA administered topically at three intraoperative
steps during THA (after acetabular preparation, femoral broaching, and at closure of the
arthrotomy) provides significant reductions in blood loss compared to placebo, with a
negligible reduction in transfusion rate55. The European TRANX-H study also provides
Level I evidence for use of topical TEA in primary THA, noting a significant decrease in
transfusion rate in the group receiving 1 gram of topical TXA infiltrated into the joint
prior to arthrotomy closure compared to placebo56. The evidence for routine use of
topical TEA, however, lags behind the literature available for topical or intra-articular
TEA in TKA. Higher-powered clinical trials are needed to further evaluate the efficacy
and safety of administering TEA topically in THA. A review of recent studies examining
the use of TEA in THA, administered both intravenously and topically, is presented in
Table 2.2.
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Table 2.2: Selected Studies Examining the Use of Tranexamic Acid in Total Hip
Arthroplasty.
Treatment Arms

Blood Loss

Transfusion

Complications

TEA = placebo

TEA = placebo

TEA = placebo

NR

TEA = placebo

TEA < placebo

TEA = placebo

TEA = placebo

TEA = placebo

TEA < placebo

TEA = placebo

NR

TEA < placebo

NR

TEA = placebo

NR

TEA = placebo

TEA < placebo

TEA = placebo

57

Benoni et al (2000)
1. IV TEA bolus 10 mg/kg at closure +
repeat 10 mg/kg bolus 3 hours later;
n=20
2. Placebo; n=19
Ekback et al (2000)58
1. IV TEA bolus 10 mg/kg at incision +
repeat 10 mg/kg bolus 3 hours later;
n=20
2. Placebo; n=20

TEA < placebo
(intraoperative)
TEA < placebo
(postoperative)

Husted et al (2003)61
TEA = placebo
(intra-operative)
1. IV TEA bolus 10 mg/kg bolus at
incision + 1 mg/kg/hr x 10 hours
postop; n=20
2. Placebo; n=20

TEA < placebo
(postoperative)
TEA < placebo
(total)

Garneti et al (2004)62
1. IV TEA bolus 10 mg/kg bolus at
incision; n=25
2. Placebo; n=25
Johansson et al (2005)60
1. IV TEA bolus 15 mg/kg at incision;
n=47
2. Placebo; n=53
Niskanen et al (2005)63
1. IV TEA bolus 10 mg/kg bolus at
incision + repeat 10 mg/kg bolus q8h x
2; n=19
2. Placebo; n=20
Yamasaki et al (2005)64
1. IV TEA bolus 1 gram bolus at
incision; n=21
2. Placebo; n=21
Ralley et al (2010)46
1. IV TEA bolus 20 mg/kg bolus at
incision; n=109
2. Placebo; n=89

TEA = placebo
(intraoperative)
TEA = placebo
(postoperative)

TEA = placebo
(intra-operative)
TEA < placebo
(postoperative)

TEA < placebo
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Treatment Arms

Blood Loss

Transfusion

Complications

NR

NR

TEA = placebo

NR

TEA < placebo

TEA < placebo

TEA = placebo

TEA < placebo

TEA < placebo

NR

TEA = placebo
(intraoperative)

TEA < placebo
(autoRBC)

65

McConnell et al (2011)
1. IV TEA bolus 10 mg/kg at incision;
n=22
2. Fibrin spray; n=22
3. Placebo; n=22
Imai et al (2012)59
T0. Placebo; n=22
T1. IV TEA 1 gram at closure; n=24
T2. IV TEA bolus 1 gram at closure +
repeat 1 gram bolus 6 hours later; n=20
T3. IV TEA bolus 1 gram at incision;
n=25
T4. IV TEA bolus 1 gram at incision +
repeat 1 gram bolus 6 hours later; n=26
Alshryda et al (TRANX-H; 2013)56
1. Topical TEA 1 gram at closure; n=80
2. Placebo; n=81
Konig et al (2013)55
1. Topical TEA 3 grams in divided
doses; n=91
2. Placebo; n=40
Oremus et al (2014)30
1. IV TEA 1 gram bolus at incision +
repeat 1 gram bolus 3 hours later; n=20
2. Placebo; n=22

TEA < placebo
TEA = fibrin
T3 < placebo
(intraoperative)
T4 < placebo
(intraoperative)
T3 < placebo
(postoperative)
T4 < placebo
(postoperative)

TEA = placebo

TEA < placebo
TEA = placebo
(postoperative)
(alloRBC)
*AutoRBC: Autologous Blood Reinfusion. AlloRBC: Allogeneic Blood Transfusion. NR : Not
Reported.

2.5 Thromboembolic Risk of Perioperative Antifibrinolytic
Therapy
To date, multiple systemic reviews, meta-analyses and randomized clinical trials,
including thousands of patients, have failed to demonstrate an increased risk of
thromboembolic events when TEA is used in primary TKA or THA, as outlined in Table
2.3. Based on the results of these studies, the risk remains theoretical. Perhaps the most
convincing evidence comes from a systematic review published in 2009, showing no
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significant difference in rates of reported thromboembolic events in 949 patients
receiving antifibrinolytic therapy as adjunctive therapy prior to TKA or THA66. Caution
must be taken when interpreting these studies; patient selection remains an important step
when considering the use of tranexamic acid. Although not always clearly stated, most
published series in TKA and THA exclude potential subjects with a medical history of
coagulopathy, cerebrovascular event(s), or any thromboembolic event. In some studies,
patients having undergone cardiac stenting, as well as females on long-term estrogen
replacement therapy have also been excluded from receiving TEA. Further evidence is
needed to supporting the administering of TEA in these higher-risk patient populations,
for any of the documented routes of administration.
Table 2.3: Systematic Reviews and Meta-Analyses Assessing Antifibrinolytics in
Lower Extremity Total Joint Arthroplasty.
Procedure

Comparison

No.
Studies

Blood Loss

Transfusion

Complications

TEA < placebo

TEA < placebo

TEA = placebo

NR

TEA < placebo

NR

All = placebo

All = placebo

67

Ho and Ismail (2003)
1° TKA
1. IV TEA
12
1° THA
2. Placebo
Cid and Lozano (2005)68
1. IV TEA
1° TKA
9
2. Placebo
Gill and Rosenstein (2006)69
1. IV TEA +
1° TKA
Apr
RevTKA
2. IV TEA
13
1° THA
3. Apr
RevTHA
4. Placebo
Zufferey et al (2006)70
1° TKA
RevTKA
23 Apr
1° THA
1. IV AFlytic
20 TEA
RevTHA
2. Placebo
2 EACA
Spine
Tumor
Kagoma et al (2009)66
1. IV AFlytics
1° TKA
(Apr, TEA and
29
1° THA
EACA)
2. Placebo
Sukeik et al (2011)71
1. IV TEA
1° THA
2. Placebo or
11
other AFlytic

All < placebo
(intraoperative)
All < placebo
(total)
Apr < placebo
NR

TEA < placebo

AFlytic =
placebo

EACA =
placebo

AFlytic <
placebo

AFlytic <
placebo

AFlytic =
placebo

TEA < placebo
(intra-operative)

TEA < placebo

TEA = placebo
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Procedure

Comparison

No.
Studies

Blood Loss

Transfusion

Complications

TEA < placebo

TEA = placebo

TEA < placebo
(postoperative)
Gandhi et al (2013)72
1. TEA (IV,
1° TKA
IA or Top)
1° THA
2. Placebo
Zhou et al (2013)73

1° THA

1. IV TEA
2. Placebo

29 IV
3 IA
1 Top

TEA < placebo

TEA < placebo
(intraoperative)
19

TEA < placebo
TEA = placebo
TEA < placebo
(postoperative)
*EACA: Epsilon-Aminocaproic Acid. Apr: Aprotinin. IV: Intravenous. IA: Intra-Articular.
AFlytic: Antifibrinolytic (includes TEA, EACA, and Apr). NR: Not Reported.
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3 TeACH-R Trial Methodology

The purpose of our study is to compare the clinical efficacy of TEA given both
intravenously prior to skin incision and topically at the time of arthrotomy closure during
THA. A single-blinded, parallel group randomized controlled trial (RCT) forms the basis
of our investigation. During the Study Initiation, Recruitment and Data Collection Phase,
the study is colloquially termed the Tranexamic Acid Comparison in Hip Replacement
(TeACH-R) Trial.

3.1 Clinical Trial Design
Well-designed randomized controlled trials provide sound Level I evidence for or against
the use of a particular intervention, in accordance with the Oxford Centre for EvidenceBased Medicine 2011 Levels of Evidence74. Our study design uses a parallel group
design, with one treatment arm receiving intravenous TEA, the other receiving topical
TEA. There is no placebo group in this trial; the active comparator is the intravenous
tranexamic acid group, as this route of administration is considered the standard of care
for primary THA at London Health Sciences Centre, University Hospital (LHSC-UH).

3.1.1 Ethics Board Approval
The Western University Health Science Research Ethics Board (HSREB#104559) and
the Lawson Health Research Institute Clinical Impact Research Committee (CRIC#R-14130) have approved the TeACH-R Trial for use of human participants in clinical
research. Documentation of HSREB approval is provided in Appendix B. The clinical
trial has also been registered into the public domain on clinicaltrials.gov
(NCT#02056444).

3.1.2 Source of Funding
The TeACH-R Trial is supported by a Resident Research Grant (RRG) valued at $5000
Canadian Dollars, distributed as part of the Internal Research Fund from the Western
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University Department of Surgery. No other sources of external funding were required to
support the administrative or logistical needs of the study.

3.1.3 Randomization
Randomization assures that best efforts are made to equalize treatment groups with
regards to demographic variables and expected prognosis. By allocating enrolled study
participants to separate treatment groups, bias for treatment outcome is minimized.
Inclusion and exclusion criteria help to define those patients screened for study inclusion
by identifying factors that are known determinants of outcome. Minimizing bias related
to unknown or uncontrollable determinants of outcome is corrected for by allocating to
treatment groups on a random basis.
There are a number of ways to randomize effectively. Computer-generated random
sequencing programs offer a straightforward and reliable method. Sealed opaque
envelope concealment is also effective, and easy to administer. With the latter technique,
however, there is the potential for error or investigator-driven allocation if envelopes are
improperly sealed, or if the result of the allocation is visible through the envelope. We
proceeded with sealed-envelope concealment, ensuring that tamper-proof manila
envelopes were opened in succession.
In an attempt to keep even numbers between the treatment groups, a block randomization
protocol was used. For every 20 participants enrolled into the study, 10 were to be
randomized to the intravenous TEA group, and 10 to the topical TEA group.
Randomization to receive either intravenous or topical TEA during primary THA
occurred prior to the start of the procedure. As outlined in Section 3.2.3, verbal consent
was obtained via telephone conversation with the potential participant prior to the
operative date. Once verbal consent was confirmed, randomization to one of the two
treatment arms proceeded.

3.1.4 Blinding
Blinding, as it relates to clinical trial research methodology, refers to the awareness of
treatment group allocation for study participants. A study is single-blinded if either the
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participant or investigator is unaware of treatment group allocation. A double-blinded
study, on the other hand, implies that both the participant and investigator are blinded.
The TeACH-R trial is blinded to patients only, as all outcome measures are objective in
nature. TeACH-R investigators responsible for consent, randomization and data
collection do not direct patient care. Patients may, however, be biased to disclose
relevant medical information in the postoperative period if left unblinded. Willingness to
disclose an adverse event could be influenced by patient perception, should he or she
know which treatment group they have been allocated to. For example, a participant may
feel that there is an increased risk of thrombotic events with the intravenous TEA; the
threshold to seek investigations for swelling or leg pain might be lower than if the
participant was not blinded to the treatment received. The investigators have designed
the study to decrease this reporting bias; patients can only find out by which route they
have received the drug after the final outpatient follow-up, at 3 months after total hip
replacement. Data was unblinded at a specific time point after recruitment (April 1,
2014) in order to perform interim statistical analysis. All outcome measures are objective
in nature, with no potential of introducing bias into the data collected as part of the
TeACH-R study protocol. Only the primary author (R.P.N.) holds access to the data;
consultant surgeons contributing to study development are not granted access to view,
edit or input data pertaining to the TeACH-R trial.

3.2 Recruitment
The recruitment phase for the TeACH-R trial began in April 2014 and is ongoing. The
process of approaching and enrolling potential participants is outlined below.

3.2.1 Eligibility
The goal of this study is to capture primary total hip arthroplasty (THA) patients who
would otherwise be receiving IV TEA as the standard of care at our institution. Inclusion
criteria are meant to represent the typical patient proceeding to elective THA, and are
listed in Table 3.1. Five of seven fellowship-trained arthroplasty surgeons at LHSC-UH
participated in the study. Two surgeons abstained from study participation. One surgeon
cited an unwillingness to administer any intra-articular agent during arthroplasty, while
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the other utilizes a direct anterior approach for primary THA in patients with a body mass
index (BMI) below 40 kg/m2. Above this level, it was felt by this surgeon that the risk of
postoperative wound problems was significant enough to warrant a direct lateral
approach, where the incision line is away from the inguinal crease and abdominal pannus
(personal correspondence). As this is not the surgeon’s preferred approach to a primary
THA, and that the baseline risk of complications in morbidly obese patients is
significantly different than the population targeted with the proposed intervention75, the
investigators decided to exclude this surgeon’s patients from TeACH-R study
participation. Patients from these two consultants were not screened nor contacted by the
TeACH-R investigators.
Table 3.1: TeACH-R Trial Inclusion Criteria.
1.
2.
3.
4.
5.
6.
7.
8.

Primary total hip arthroplasty.
Primary diagnosis of osteoarthritis, rheumatoid arthritis, or avascular necrosis affecting
the operative hip joint.
Age over 18 years.
Plan for cementless hip implant system.
Plan for modified direct lateral (Hardinge) approach, in the lateral decubitus position.
Medically fit for elective surgery.
Consent obtained for blood product administration.
Ability to read and write in the English language.

If the criteria for TeACH-R study inclusion were met at this stage, the subject was
considered a potential study participant, but could still be disqualified from study
participation if he or she met any of the exclusion criteria listed in
Table 3.2. Exclusion criteria are focused on THA patients with additional risk factors for
venous thrombotic events (VTE) as well as those with atypical diagnoses requiring THA.
Patients at higher risk of VTE require thorough medical review prior to treatment with
TEA, and do not represent the population targeted with this intervention. The therapeutic
safety of TEA has not been thoroughly studied in patients at moderate- and high-risk;
investigators have expressed concern in administering a clot-stabilizing drug to a highrisk patient undergoing a moderate- to high-risk procedure.
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Table 3.2: TeACH-R Trial Exclusion Criteria.
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.

Primary total hip arthroplasty for the treatment of acute hip fracture.
Primary diagnosis of post-traumatic osteoarthritis (including those with or without the
need for removal of hardware prior to prosthetic implantation), or Charcot arthropathy in
the operative hip joint.
History of developmental dysplasia of the hip, slipped capital femoral epiphysis or LeggCalvé-Perthes disease in the operative joint.
Simultaneous bilateral primary THA.
History of VTE in last 12 Months, for any reason.
Lifelong anticoagulation prescribed or recommended for prior VTE.
Concurrent active malignancy receiving chemo- or radiation therapy, or having received
said therapy in the past 12 months.
Mechanical cardiac valve requiring lifelong therapeutic anticoagulation.
Drug-eluting cardiac stenting within the previous two years to treat coronary artery
disease, with ongoing clopidogrel (Plavix) therapy.
Documented coagulopathy, blood dyscrasia, or hematologic condition/malignancy.
Documented diagnosis of hemochromatosis with elevations of hemoglobin above normal
range (> 170 mg/dL), or requiring recurrent phlebotomy.
Documented allergy to TEA.
Preoperative autologous blood donation.
Inability to attend scheduled follow-up appointments with the treating surgeon.
Participation in a concurrent research study at the time of THA

Atypical presentation of degenerative hip disease as a consequence of disease processes
such as developmental dysplasia of the hip (DDH), slipped capital femoral epiphysis
(SCFE) and Legg-Calvé-Perthes disease (LCPD) are relatively rare. These pathologies
tend to affect patients decades earlier than the typical sufferer of OA, given the
manifestation of these conditions in childhood. Younger patients typically have
competent hematopoietic and cardiovascular systems, and are typically better able to
withstand the physiologic stress of major orthopaedic surgery compared to those of
advanced age. However, this population may still glean benefit from a reduced risk of
transfusion, especially in young females of childbearing age. The risk of development of
autoantibodies possibly affecting future pregnancies is not insignificant in a young
female after transfusion of blood products. However, the surgical procedure is often
more involved than the standard THA, due to the longstanding nature of hip pathology
with consequent anatomic abnormalities. In LCPD and SCFE, altered femoral head
shape can lead to significant bone loss in and around the acetabulum. Surgeons
incorporate structural bone grafts or metallic augments to support the implanted
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acetabular shell given these bony deficiencies. Dealing with these bone defects adds time
and labor to the standard THA. Hip dysplasia surgery may also require femoral
shortening osteotomies in severe deformities to bring the hip center back to its anatomic
position. These accessory steps within the procedure, not commonly performed in
elective primary THA, prolong the time of surgery and increase blood loss. Moreover,
additional manipulation of the operative extremity can increase the risk of clot formation
due to repeated endovascular disruption. From a research methodology perspective,
these factors are significant confounders, and have the potential to skew the data in an
unfavorable manner. Although TEA may be of benefit, patients affected by these disease
processes are not representative of the typical arthroplasty patient population. Given the
lack of evidence supporting the use of TEA in patients with these primary diagnoses,
patients with DDH, LCPD and SCFE in the operative extremity were excluded from the
TeACH-R study.
Adult avascular necrosis (AVN) of the hip represents a different etiological entity than
those mentioned above. Subjects with AVN as a primary diagnosis are eligible for study
inclusion. AVN often results in irreversible femoral head collapse due to weakening of
subchondral bone. Clinical presentation is variable. Altered joint motion due to the
misshapen femoral head results in progressive degenerative changes within the hip joint.
Often, clinical deterioration is rapid compared to OA or inflammatory arthritis, and
symptomatology dictates the need for THA early in the natural history of this aggressive
disease. Femoral or acetabular bone loss is infrequently seen in AVN; therefore the
surgical procedure is typically similar to a standard cementless primary THA for primary
OA. For this reason, TEA can still be of benefit in patients affected by this disorder.
Subjects with inflammatory arthropathy as a primary diagnosis are eligible for study
inclusion. Rheumatoid arthritis (RA) is a common form of inflammatory arthropathy.
The inflammatory process within the hip joint results in both erosive and degenerative
changes heralding the need for THA. The patient with inflammatory arthropathy often
has concurrent alterations in their hematologic profile, with decreased hematopoietic
potential. Commonly, these patients are anemic preoperatively and have pre-formed
autoantibodies as a result of immunologic dysregulation. The prevalence of anemia in
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patients with RA is thought to be anywhere from 30 to 60 percent. In combination, both
iron-deficiency anemia from longstanding anti-inflammatory use and anemia of chronic
disease due to autoimmune attack on hematopoietic cells within the bone marrow
contribute to the increased prevalence of anemia in RA patients76. Avoidance of
transfusion in the rheumatoid population is therefore paramount; procuring an allogeneic
match is often difficult, costly, time-consuming, and exposure to repeated transfusion
increases the risk of forming additional allo-antibodies77. The benefits of administering
TEA far outweigh the risks for the patient with inflammatory arthropathy needing THA
for the management of symptomatic hip disease.

3.2.2 The Preoperative Medical Evaluation
Once the determination has been made to proceed with surgery to replace the
degenerative hip joint, all arthroplasty patients at LHSC-UH undergo a thorough medical
review in the Pre-Admission Clinic (PAC). This is in addition to the orthopaedic-specific
medical history taken at the time of initial consultation with the treating surgeon. At this
PAC visit, Orthopaedic Nurse Practitioners (ONP) are tasked with performing a thorough
review of systems, documenting all preoperative medications, and placing day-ofprocedure orders, to be implemented as the patient arrives to the Surgical Preparation
Unit on the day of the elective procedure. Specialist Internal Medicine or Anaesthesia
consultations are completed during the PAC visit, should the need arise based on medical
conditions identified during the orthopaedic consultation or ONP medical review.
Timing of the PAC visit is meant to provide up-to-date medical information to all
involved in the care of the arthroplasty patient. The planned date of the surgical
procedure is known, and the PAC appointment is scheduled anywhere from 1 week to 3
months prior to the surgical date. This allows for enough time preoperatively to order
urgent investigations, if necessary, and to advise on medication profile alterations,
without changing the date of surgery. Updated blood work, including a complete blood
count (CBC), is drawn if the planned procedure is more than 3 months from the date of
the most recent available values. The CBC includes the hemoglobin (Hgb) and
hematocrit level (Hct); values nearest to the operative date and time are used as baseline
for the calculation of perioperative blood loss in this study.
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The order for TEA is placed electronically at the PAC visit, along with other day-ofprocedure orders. The ONP is responsible for assessing the need and eligibility for
intraoperative TEA administration, based on the Medical Directive set by the
Perioperative Blood Conservation Program (PBCP). The latter outlines the
circumstances where TEA can be given safely to patients undergoing both THA and
TKA (See Appendix D). The majority of arthroplasty patients fall into one of two
categories: (1) no concern exists with regards to TEA administration, or (2) an absolute
contraindication exists within the patient’s medical profile. In the first scenario, the ONP
places the order after the PAC encounter is completed. In the latter scenario, no TEA
order is placed on the chart.
If any element of the patient medical history raises concern with regards to the safety of
administration of TEA, further review by the PBCP is indicated. The PBCP is composed
of a number of specialist physicians, including hematologists, surgeons and
anaesthesiologists, whose main responsibility is the creation of policies to optimize the
use of cost-effective and safe blood conservation protocols in the perioperative setting.
On a case-by-case basis, three individuals work in unison to determine eligibility for TEA
administration: a supervising physician with subspecialty interest in perioperative
medicine and blood conservation (the Director), working in direct consultation with two
PBCP nurse practitioners. Final determination of perioperative TEA administration in
equivocal cases comes after the PCBP Director performs a thorough medical review and
risk-benefit analysis. This process is unaffected by the TeACH-R protocol.

3.2.3 Informed Consent
Informed consent for study participation was obtained pre-operatively for all study
participants. The process of informed consent was undertaken as per Good Clinical
Practice (GCP) standards. Possible study participants were identified by thorough review
of surgical lists. A chart review was undertaken for subjects meeting TeACH-R study
inclusion criteria. If no exclusion criteria were identified based on the available
information contained within the subject’s chart, contact was made prior to the day of the
procedure, either by telephone or at the PAC visit. Usually, the study participant had
completed the PAC appointment with day-of-procedure orders visible on the electronic

41

chart before being contacted by a member of the research team. This process enabled the
research team to select study participants whom had already been ordered TEA by either
the ONP or PBCP.
Verbal consent was obtained at the time of initial patient contact. Written informed
consent was then obtained on the morning of surgery, where the study objectives and
protocol were reviewed, and all questions answered. A copy of the written consent form
is provided in Appendix C. Subjects were deemed to be enrolled in the study only after
written informed consent was signed and dated; the option to decline participation was
allowed up until this point. Should a patient enrolled in the topical TEA treatment arm
decline participation preoperatively, he or she would still receive the standard of care,
intravenous TEA, prior to skin incision. Consent can be retracted postoperatively, at the
participant’s request. Although he or she would have received treatment based on
randomized allocation to a treatment arm, participant data is not to be included as part of
the final analysis.
Signed original consent forms are kept in a locked room in a secure facility at University
Hospital. The Western HSREB requires that these consent forms be maintained for ten
years after completion of the enrollment phase of the TeACH-R study. A copy of the
signed consent form was provided to all study participants at the time of formal study
enrollment.

3.3 Treatment Arms
3.3.1 Intravenous Tranexamic Acid
At LHSC-UH, intravenous TEA is given to all patients undergoing primary THA so long
as a particular patient does not have a contraindication to TEA administration. This is
considered standard of care for both TKA and THA. Preparation of the medication is
done the night prior to the procedure, by the Inpatient Pharmacist, with a weight-based
dose of 20 mg/kg TEA mixed in a 50 mL bag of 0.9% sodium chloride. This is
refrigerated overnight at 4° Celsius, sent to the Surgical Preparation Unit on the morning
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of surgery and appended to the patient’s chart (see Figure 3.1). The preparation travels
with the patient to the Operating Room (OR), where it is administered 10 minutes prior to
skin incision for THA via intravenous injection by the anaesthesiologist assigned to the
OR on that particular day. For the purposes of this study, intravenous TEA is considered
active five minutes after completion of the infusion, as the drug has had enough time to
redistribute into the joint space.

Figure 3.1: Intravenous Tranexamic Acid Preparation.

As discussed in Chapter 2, both single-dose and serial dosing TEA regimens are
prevalent in the literature. Logistical barriers related to patient transport, equipment, and
nursing exist in the perioperative setting that can impair the implementation of a reliable
multi-dose or TEA-infusion protocol. We elected to use a single-dose regimen of 20
mg/kg given immediately prior to skin incision. This protocol is the standard of care
currently in use at LHSC-UH for THA. This has proven effective at our institution in
reducing blood loss without a concomitant rise in thromboembolic events post-THA46.
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3.3.2 Topical Tranexamic Acid
Topical TEA is prepared in a similar fashion to the intra-articular preparation used in
TKA. Like the intravenous TEA group, the Inpatient Pharmacist prepares the solution
the night prior to the procedure. However, in the topical TEA group, a standardized
solution of 1.5 grams in a 50 mL solution of 0.9% sodium chloride is prepared. The
solution is contained within a sterile syringe sent to the Surgical Preparation Area, and
subsequently to the OR with the study participant (see Figure 3.2). For subjects allocated
to this treatment arm, no intravenous TEA is administered prior to skin incision. Instead,
the solution is applied to the joint area intraoperatively by the treating surgeon. This
takes place with the final implants in situ after final reduction of the prosthetic
components. The entirety of the 50 mL TEA solution is applied to the joint prior to
closure of the gluteus minimus and capsular tissue layers. The solution bathes the hip
joint and surrounding tissues for a minimum of 5 minutes. Closure of the arthrotomy can
continue during this waiting period, provided the solution is not suctioned away.

Figure 3.2: Topical Tranexamic Acid Preparation.

Timing and dosage are important considerations when TEA is administered via the
topical route. Optimal timing of administration must parallel the timing of expected
increases in blood loss. In THA, the majority of intra-articular blood loss emanates from
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cancellous bone at the sites of the femoral neck osteotomy and acetabular reaming. This
continues postoperatively until local hemostasis is achieved. We elected to target
reductions in perioperative blood loss by infiltrating TEA after the intramedullary
femoral canal has been filled with the stem of the press-fit femoral implant, and the
acetabular cup sealed with the press-fit shell. In this fashion, we target sites of continued
postoperative bleeding not amenable to electrocautery or ligation. This corresponds
primarily to the exposed cancellous bone of the proximal femoral shaft, where TEA can
act to inhibit the local fibrinolytic process postoperatively. In a recent study, Konig et al
infiltrated 3 grams of TEA at three separate time points intraoperatively with good
clinical outcomes with regards to blood loss55. In principle, this represents a useful
strategy to maintain intra-articular does of TEA from the start through to the end of the
operation. However, the investigators and arthroplasty surgeons felt the additional doses
would result in intraoperative time delays due to the mandatory waiting period after TEA
infiltration, potentially increasing the risk of infection. A single-dose regimen targeting
the predominant source of blood loss was adopted for the purposes of this study.
Dosage of topical TEA was also an important consideration in the development of this
study. There is little available evidence to guide the optimal dosing protocol for topical
TEA administration in THA. However, to reiterate the aforementioned study by Wong et
al, a 1.5 gram topical dose of TEA was shown to be effective in reducing blood loss when
administered during TKA, with a clinically favorable systemic absorption profile39.
Using this data, we chose to proceed with the identical dosing strategy for TeACH-R
study participants undergoing primary THA. As surgical drains are no longer standard
practice amongst the arthroplasty surgeons at our institution for THA, serial dosing of
topical or intra-articular agents is not possible in the postoperative period.

3.4 Surgical Considerations
3.4.1 Operative Technique
A thorough description of key principles and approaches for THA is available in Section
1.2.1.1. The standard operative procedure for a primary cementless THA has been
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defined for the purposes of this study. The modified direct lateral (Hardinge) approach,
using a surgical incision based over the greater trochanter, was used for all study subjects.
The gluteus minimus and capsular tissue layers were incised as one layer. The capsule
was not excised following the arthrotomy. No restrictions were defined regarding the
sequence of femoral and acetabular preparation, trialing of expected components, or
prosthetic implantation. No surgical drains were placed intraoperatively. All patients
received the standard weight-based dose of intravenous antibiotics within 30 minutes of
skin incision. Typically, cefazolin is the antibiotic of choice. In cases of severe allergy
or colonization with methicillin-resistant Staphylococcus aureus (MRSA), vancomycin
and/or clindamycin are either substituted or added to the preoperative regimen. To the
best of the author’s knowledge, there are no known drug interactions between TEA and
any of these intravenous antibiotics.

3.4.2 Prosthetic Components
When it comes to primary hip prostheses, a variety of implants are used at LHSC-UH.
As per the TeACH-R protocol, choice of final prosthesis and bearing surface is at the
discretion of the treating surgeon, as long as cementless fixation is used on for both the
femoral stem and acetabular shell. If the latter criterion is not met, the patient is excluded
from the study. This situation arises most commonly when there is concern of
diminished bone density, identified intraoperatively, where cemented implants are
thought to provide improved stability in the setting of poor osteo-integrative potential.
The use of adjuvant screw placement through the acetabular component was also left to
the discretion of the treating surgeon. Participants requiring acetabular screw placement
as an added measure of stability were not excluded from the final analysis. Because
placement of acetabular screws tends to increase operative time and increases the risk of
bleeding, screw fixation was noted in the final analysis as a demographic variable.
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3.5 Postoperative Care of the Arthroplasty Patient
3.5.1 Inpatient Care After Elective Primary Total Hip Arthroplasty
All patients undergoing total hip arthroplasty follow a standard postoperative pathway.
The patient is transferred from the OR to the Post-Anaesthetic Care Unit (PACU) for
close monitoring after completion of the period of anaesthesia. While in the PACU, the
treating anaesthesiologist manages multi-modal analgesia protocols as well as any acute
medical issues. A plain film radiograph of the pelvis is taken in the PACU shortly after
arrival in order to assess the position of the implanted components and to rule out
prosthetic dislocation or unidentified intraoperative fracture. Occasionally, a CBC is
drawn in the PACU in cases in which there has been an unusual amount of bleeding intraoperatively.
Once the patient is deemed medically stable, he or she is transferred to the orthopaedic
floor for continued rehabilitation and convalescence. On the inpatient orthopaedic floor,
the focus of treatment is on early mobilization in order to reduce the incidence of
postoperative complications. The surgical team rounds on each arthroplasty patient a
minimum of once per day, monitoring for complications and tracking progress with
mobilization. Daily blood work is routinely drawn the first two mornings after the day of
surgery. Standard postoperative blood work consists of a basic hematology, coagulation
and chemistry panel: CBC, electrolytes (sodium, chloride, potassium, bicarbonate and
random glucose), blood urea nitrogen (BUN), creatinine (Cr), International Normalized
Ratio (INR) and partial thromboplastin time (PTT). Supplementary investigations are
dependent on clinical suspicion of postoperative pathology, or for monitoring of known
medical conditions, drug levels, or therapeutic targets. This study does not alter the usual
sequence of postoperative investigations. There is no additional screening or testing
mandated by the TeACH-R study protocol.
Throughout the inpatient stay, there is a gradual increase in activity level, with the
treating surgeon ultimately dictating weight-bearing restrictions based on personal
preference and intraoperative findings. Implementation of hip precautions after surgery
is standardized as per the pathway for THA postoperative care at LHSC-UH. Patients are
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advised against hip flexion past 90° and excessive internal or external rotation of the
thigh in order to prevent prosthetic dislocation. Given these restrictions, a gait aid is
usually required for the first 6 weeks postoperatively, which is started in hospital on
postoperative day 1. Physio- and occupational therapists see arthroplasty patients in
hospital and provide daily education and assistance, enabling progression of mobility in
preparation for a safe discharge from hospital. Readiness for discharge is a multi-faceted
process with influence from various members of the interdisciplinary care team, where
significant emphasis is placed on the patient’s perception of ability to cope at home,
support systems available to help in recovery, and general medical condition. Typically,
patients are ready for discharge on postoperative day two or three following primary
lower extremity arthroplasty. The usual discharge prescription consists of pain
medication(s) and a thromboprophylactic agent to be taken on a routine basis once at
their discharge destination.

3.5.2 Thromboembolic Prophylaxis after Primary Total Hip
Arthroplasty
Major orthopaedic surgery, which includes THA, is a known risk factor for the formation
of lower extremity clot. A deep vein thrombus (DVT), or blood clot, forms due to a
combination of factors related to Virchow’s triad of vascular thrombosis: endothelial
injury, hypercoagulability and vascular stasis78. First, endovascular damage results from
manipulation of the operative leg. Second, the release of procoagulant factors during
bone preparation results in a hypercoagulable state that can persist in the postoperative
period79, 80. Third, relative immobility during the convalescence phase promotes clot
propagation due to venous stasis. If a clot increases to the point of impeding proper
venous outflow in the affected limb, leg pain and diffuse unilateral swelling ensue,
usually in the operative extremity.
Doppler ultrasonography of the lower extremity leg veins is the most commonly used
method of providing a definitive diagnosis, showing poor compressibility of veins having
a DVT. Pulmonary emboli (PE), on the other hand, are embolic phenomena. A clot in
the operative (or non-operative) extremity dislodges from its endovascular source and
subsequently travels through the inferior vena cava, through the right atrium and ventricle
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past the tricuspid and pulmonic valves, to eventually lodge in the smaller arteries of the
lung. The latter can have a variable presentation in the postoperative period. Chest pains,
shortness of breath, supplemental oxygen dependence, and/or unremitting tachycardia (in
the absence of any other clinical explanation) are clinical scenarios that can herald the
onset of thrombus migration to the lungs. Suspicion for thromboembolic events must be
high after primary or revision THA because there is a risk of mortality associated with an
unrecognized embolism. Diagnosis is confirmed with either a ventilation-perfusion scan
or computerized tomography of the thorax with concomitant pulmonary arterial and
venous angiography. Generally, a low threshold exists for investigating a potential clot.
Although many promote screening for a lower extremity thrombus after arthroplasty,
high clinical vigilance and early investigation remains the standard of care in this patient
population. Not all clots are symptomatic, nor do all clots require full anticoagulant
therapy. The rate of symptomatic or fatal emboli remains unaffected by the presence of a
radiographic DVT screening protocol, hence it is not recommended by the American
College of Chest Physicians in their most recent guideline statement17. Moreover, there
is currently no evidence to support an increased risk of thromboembolism in patients
receiving TEA during TKA or THA66, 72. In keeping with the standard of care at LHSC,
routine radiographic screening with duplex ultrasonography is not part of the TeACH-R
trial protocol.
Postoperative thromboprophylaxis remains part of the postoperative care pathway after
primary total hip arthroplasty at LHSC-UH. Many agents, including unfractionated
heparin (UFH), low-molecular-weight heparins (LMWH), vitamin K antagonists, factor
Xa inhibitors (FXaI) and direct thrombin inhibitors (DTI) are effective in decreasing
thromboembolic risk using prophylactic dosing regimens17. The TeACH-R study
protocol does not discern which thromboprophylactic agent is used, so long as the study
subject is on a prophylactic dose postoperatively. Prior to TeACH-R study initiation, the
group of arthroplasty surgeons at LHSC completed a thorough review of the current
evidence on thromboembolic prophylaxis after primary total hip arthroplasty. The group
of surgeons using the modified Hardinge approach for THA universally adopted oral
rivaroxaban 10 mg daily, given in the morning starting postoperative day 1 and
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continuing for 30 days postoperatively. Rivaroxaban is a Factor Xa inhibitor growing in
popularity as a result of well-documented clinical efficacy as a thromboprophylactic
agent, with the ease of once-daily oral administration20. The agreed-upon regimen was
deemed to be safe, effective, and better tolerated by patients compared to subcutaneous
LMWH, which had been the predominant agent used in the past.
The thromboprophylaxis regimen at LHSC-UH uses chemical thromboprophylaxis alone,
without the addition of external compression devices. Adding intermittent compression
devices, foot pumps and/or compression stockings is not the standard of practice, as these
are deemed to be a constant source of patient discomfort, and are a significant
impediment to mobility during the in-hospital stay. The benefits of early mobilization
free of any lower extremity device outweigh the benefit of these external devices.
Implantable inferior vena cava filters are not used for prophylaxis due to the invasive
nature of the procedure and marginal clinical benefit.
Data pertaining to which thromboprophylaxic agent a TeACH-R participant received at
time of discharge is recorded as part of the study. Of note, a separate clinical trial
comparing two DVT prophylaxis protocols combining rivaroxaban and acetylsalicylic
acid after elective primary THA (the EPCAT-II Study) was underway at LHSC-UH at the
same time as the TeACH-R Trial. Because of the possible influence of this latter study
on rates of DVT and PE, any patient enrolled in EPCAT-II was excluded from TeACH-R
study participation.

3.5.3 Transfusion Protocol
As discussed in Section 1.4.2, strong evidence supports limiting transfusion of packed red
blood cells (pRBC) in the acute care setting in order to decrease morbidity and mortality.
Although there are no studies specific to THA, there is definitive evidence stemming
from two prospective randomized controlled trials, one in critically ill patients patients22,
and the other in patients having received hip fracture surgery27. As a result, a restrictive
transfusion protocol is the standard of care for the arthroplasty service at LHSC-UH.
TeACH-R study investigators responsible for data collection and analysis, although not
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directly involved in the postoperative treatment of a study subject, support this
transfusion strategy, as outlined in Figure 3.3.

Figure 3.3: Restrictive Transfusion Algorithm for Postoperative Anemia in
Arthroplasty Patients at London Health Sciences Center, University Hospital.

Violations of the restrictive transfusion strategy were recorded. If a transfusion of
pRBCs was initiated, all clinical notes from the inpatient stay were reviewed in an
attempt to find a documented reason for transfusion. The number of units administered
was recorded as per the TeACH-R trial protocol.
Preoperative autologous blood donation (PAD) and postoperative reinfusion (PRI) of
drained blood after arthroplasty, although not used at LHSC-UH, is still commonplace in
certain centers. Issues in incorporation of these modalities as perioperative blood
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conservation adjuncts are discussed in Section 1.4.3. Subjects are excluded from the
TeACH-R trial if these modalities are used in the perioperative period.

3.5.4 Outpatient Follow-Up
At LHSC-UH, patients undergoing THA have scheduled follow-up with the treating
surgeon at the 6-week, 3-month and 1-year mark. Depending on surgeon preference, a
patient may also be seen at the 2-week mark for a wound check. At time of discharge
from hospital, the first two clinic appointments are coordinated with the surgeon’s office.
Patients are given strict instruction to contact a member of the surgical team should there
be any concern related to their surgery in the early postoperative period. During business
hours, patients can contact the surgeon’s office directly; after discussion with a member
of the surgical team, the decision is made to either see the patient in clinic or if urgent, to
proceed to the Emergency Department at University Hospital for further evaluation.
Outside of usual business hours, patients have direct telephone access to the on-call
orthopaedic resident at University Hospital. This has traditionally been a well-developed
process for identifying, treating and documenting complications locally.
TeACH-R study participants are followed for 3 months after surgery. Contact is made
with the patient at 2 weeks, 6 weeks and 3 months postoperatively, usually in person at
the time of outpatient follow-up, where a member of the research team assesses for the
presence of any postoperative complications. If in-person contact is not possible,
completion of the questionnaire is via telephone correspondence by a member of the
research team. All clinical notes are reviewed, also with the goal of identifying any
complications related to the new intervention that are not disclosed by the subject. The
TeACH-R study protocol does not mandate any repeat blood work or additional
investigations at outpatient clinic follow-up appointments. Loss to follow-up is noted in
the final analysis.
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3.6 Data Collection
Data collection began once the patient has been formally enrolled into the study, has been
randomized to one of the two treatment arms, and continues his or her postoperative
course up to the three-month follow-up appointment with the treating surgeon. All data
is collected prospectively. At LHSC-UH most of the available data is contained on the
patient’s electronic chart (PowerChart, Cerner Corporation, Kansas City, MO), although
at times reference to the participant’s paper chart is required for further information.
Data collected is devoid of identifiable patient information, with representative study
identification numbers assigned to all TeACH-R trial participants. All collected data is
contained within study binders stored in a secure location in a locked office, accessible
only to TeACH-R trial investigators. A password-protected Microsoft Office Excel
spreadsheet (Microsoft Corporation, Redmond, WA) also contains de-identified
participant data for analysis. This is stored on a secure server (the P: drive) within the
LHSC computer system, accessible only via secure user login. In this fashion,
confidentiality of patient information is ensured throughout the data collection phase.
The author (R.P.N.) collected all data relevant to the TeACH-R Trial.

3.6.1 Demographics
The purpose of collecting demographic data in a prospective randomized controlled trial
is to ensure that both treatment groups are similar at baseline after randomization. With
an appropriate sample size and similar profiles, potential between-group differences in
the dependent variable(s) are related to the variable controlled by the study itself
(independent variable); in this study, this would be administration of either intravenous or
topical TEA. All demographic variables collected as part of the TeACH-R study are
listed in Table 3.3. In addition to basic demographic variables, a number of variables
pertaining to the surgical procedure and comorbidities were also collected.
Table 3.3: TeACH-R Demographic Variables.
Patient-Specific Demographic Data
Age (at Time of Surgery)
Gender
Height (cm)
Weight (kg)
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Body Mass Index (BMI; kg/m2)
Body Surface Area (BSA; m2)
Primary Diagnosis (OA, RA, AVN)
Preoperative Anemia (Hgb<120 in females, Hgb<130 in males)

Medical Comorbidities (Charlson Age-Comorbidity Index)
Previous Myocardial Infarction
Congestive Heart Failure
Peripheral Vascular Disease
Cerebrovascular Disease (Stroke, Transient Ischemia Attack)
Dementia
Chronic Obstructive Pulmonary Disease
Connective Tissue Disease
Peptic Ulcer Disease
Diabetes Mellitus (with and without End-Organ Damage)
Moderate to Severe Chronic Kidney Disease
Hemiplegia
Leukemia
Malignant Lymphoma
Solid Tumour
Liver Disease (Mild, Moderate or Severe)
Acquired Immunodeficiency Syndrome (AIDS)

Intraoperative Variables
Duration of Procedure
Type of Anaesthesia (General or Regional with Sedation)
American Society of Anaesthesiologists (ASA) Physical Status Score
Acetabular Screw Placement

3.6.1.1

Combined Charlson Age-Comorbidity Index

The presence of medical comorbidities is known to alter the risk of postoperative
complications after THA. Therefore, assessing the aggregate baseline risk level for each
treatment group is essential. As de Groot stated in his 2003 article, “comorbidity can
either act as a confounder, threatening the internal validity, or as an effect modifier,
threatening the internal and external validity of the study.”81 The difficulty in assessing
preoperative risk based on comorbidities lies in filtering through the variety of medical
diagnoses of relevance, as well as the numerous methods at our disposal to assess
preoperative risk.
The Charlson Comorbidity Index, initially described in 1987, is a weighted scale
inclusive of 19 disease processes, listed in Table 3.3, that has proven to be a useful tool in
prognosticating outcomes82. It is also user-friendly, comprehensive, and most
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importantly, predictive. The structure of the index allows straightforward assessment of
risk factors for perioperative complications, in addition to prognosticating long-term
morbidity and mortality. It is validated for use in arthroplasty, as it has shown excellent
validity for mortality, disability, hospital readmission and length of stay81. When a
combined age-comorbidity score is used, the impact of increasing comorbidity is easy to
understand, as per Gold in his 1994 article: “the estimated relative risk of death from an
increase of one in the comorbidity score proved approximately equal to that from an
additional decade of age.”83 After a thorough review of the available methods, the
TeACH-R study investigators felt the combined age-comorbidity score would provide the
more reliable measure of assessing known preoperative comorbidities for the purpose of
baseline comparison between both of the treatment arms.

3.6.1.2

Intraoperative Variables

When designing a procedure-related RCT, analysis of intraoperative variables is also
critical, as there can be subtle differences in process for two patients receiving the same
operation. Intraoperative proceedings, and how they compare to the standard operating
procedure, are difficult to assess given the significant heterogeneity in patient anatomy,
physiology and surgeon preference. Thankfully, there is available data contained within
the Intraoperative Record, Anaesthetic Record and Operative Report that allows for some
standardization between both treatment arms.
For every patient proceeding to the OR, the attending anaesthesiologist, a specialist in
perioperative medicine, places significant importance on a through review of medical
conditions prior to induction of anaesthesia. The American Society of Anaesthesiologists
(ASA) Physical Status Score is still commonly used as a standard measure of operative
risk, despite concerns surrounding scientific precision and limited inter-observer
reliability84. The classification system is presented in Table 3.4. The attending
anaesthesiologist states and records the ASA Score at the beginning of every case, as part
of the World Health Organization-mandated surgical debriefing. This is also recorded as
per the TeACH-R Trial protocol. Although less robust than the Charlson AgeComorbidity Index, it provides an added measure of assessing preoperative risk based on
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comorbidity and is helpful in assessing for any baseline between-group differences, in the
eyes of the anesthesiologist.

Table 3.4: ASA Physical Status Classification System.
A normally healthy patient.
Class 1
A patient with mild systemic disease.
Class 2
A patient with severe systemic disease.
Class 3
A patient with severe systemic disease that is a constant threat to life.
Class 4
A moribund patient who is not expected to survive without the
Class 5
Class 6

operation.
A declared brain-dead patient whose organs are being removed for
donor purposes.

The type of anaesthesia is also collected as part of the TeACH-R data set. Although
beyond the scope of this study, the influence of the type of anaesthesia, and its resultant
effect on surgical outcome after TKA or THA, continues to be debated amongst
anesthesiologists worldwide given a lack of recent high-powered clinical trials. Metaanalysis data does, however, suggest that regional anaesthesia decreases operating time
and the risk of postoperative thromboembolism when compared to general anaesthesia in
THA85. There is also a significant effect on surgical blood loss, with decreased
transfusion requirements reported for THAs done under spinal anaesthesia86. In general,
the TeACH-R protocol places few restrictions on the intraoperative process. No patient
was included or excluded from the study based on whether they received general or
regional anaesthesia, but this data was recorded for every study participant.
From the surgical standpoint, increased surgical time leads to increased blood loss if a
constant rate of loss is maintained for the duration of the procedure. The precise start and
end time of the procedure was also collected from the Intraoperative Record as part of the
TeACH-R study protocol. The need for acetabular screw fixation, sometimes required to
add stability to the acetabular implant after reaming in poor-quality bone, is not expected
to add significantly to perioperative blood loss as the screws are sealed within the
implanted shell and threaded into the cortico-cancellous bone of the pelvis. These are
placed at final implantation of the acetabular component. However, the risk of arterial or
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venous injury potentially leading to hemorrhage and blood loss increases with faulty
screw placement in an at-risk zone. The addition of this intraoperative step also increases
operative time, although generally by a small amount. For these reasons, both variables
were also recorded as baseline measures and potential statistical confounders.

3.6.2 Primary Outcome Measures
The benefit of introducing TEA into the usual blood conservation for a patient
undergoing primary THA is to further decrease blood loss. The predominant risk of
administering a clot-stabilizing agent during THA is the potential for increased rates of
thromboembolic complications in the postoperative period. The primary and secondary
outcomes measured by the TeACH-R trial attempt to encompass these risks and benefits
by the most reliable means possible.

3.6.2.1

Change in Hemoglobin Levels (Delta-Hemoglobin)

The delta-hemoglobin (ΔHgb), defined for the purposes of the TeACH-R trial as the
difference between the Hgb value nearest the date of surgery and the lowest measured
postoperative Hgb, represents a main driver of clinical decision-making with regards to
the need for transfusion for the control of postoperative blood loss. It represents one of
two primary outcomes measures of the TeACH-R trial. Clinically, should clinical
concern of acute hemorrhage exists, the first investigation ordered is often a CBC for the
purposes of determining a Hgb level. The preoperative Hgb level, a prerequisite for any
patient undergoing a major surgical intervention where a significant amount of blood loss
is expected, is also an intuitive marker of underlying red blood cell mass. Decreases in
postoperative Hgb level represent loss by one of two mechanisms: (1) external loss
(hemorrhage) or (2) intrinsic red cell degradation (hemolysis). In the immediate
postoperative setting, interpretation of Hgb levels is straightforward, requiring little
calculation or analysis as loss of red cell mass is predictably due to continued
extravasation of intravascular volume outside the vascular tree. Given the period of 120
days needed for a reticulocyte to mature into a functioning red blood cell, anemia due to
lack of production of red blood cells is limited to chronic, rather than acute etiologies of
blood loss.
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Blood analysis for Hgb levels can be performed rapidly, enabling point-of-care decisionmaking in times of need. The classic clinical presentation of blood loss after THA is
more gradual in onset, and the treatment consists of transfusion of pRBC as per the
protocol outlined in Figure 3.3. Typically, a low Hgb level is discovered incidentally as
part of the routine postoperative blood work. As explained in Section 3.5.1, postoperative
blood work is available for the patient’s in-hospital stay, which is used to calculate the
ΔHgb in the TeACH-R trial. Unless there is concern for early postoperative infection, no
further blood work is indicated once discharged from hospital.
The clinical utility of the Hgb level as a transfusion trigger is well documented.
However, assessing surgical blood loss based on either isolated Hgb values, or the change
in Hgb lacks precision. Commonly used as a surrogate marker of blood loss, it is
important to note the various factors contribute to one isolated Hgb value drawn in the
perioperative setting. One cannot accurately calculate the amount of blood lost using
Hgb values alone, for a number of reasons. A falsely elevated Hgb level may result if
bloodwork is drawn while there is continued bleeding. Dilution by crystalloid or colloid
intravascular fluid administration can also alter the apparent red cell mass due to intraand extravascular fluid shifts. Intraoperative irrigation and suctioning can also alter the
systemic fluid balance, resulting in potential hemodilution. Specific to research
methodology, however, there is great value in interpreting this measure as a scale when
used as a comparator between groups, assuming that contribution of the other factors to
Hgb levels remains constant amongst all participants. In this way, a significant
difference in the ΔHgb can still indicate a difference in blood loss between groups. For
this reason, the determination of ΔHgb in the perioperative setting remains an invaluable
aid in the assessment of blood loss, which explains its use as a primary outcome in this
prospective randomized controlled trial.

3.6.2.2

Calculated Red Blood Cell Loss

Determining the amount of surgical blood loss is a difficult endeavor, as the value that is
truly of interest is actually the volume of red blood cells lost during and after the
procedure. Red blood cells are the transporters of oxygen within the systemic circulation;
it is the global increase in oxygen-carrying capacity that transfusion of red blood cell
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aims to improve. Given that fluid status changes during and after surgery are dependent
on the concentration of intra- and extracellular proteins, this can be challenging to predict
and manage, let alone calculate accurately. There are a number of ways investigators
have attempted to quantify perioperative blood loss in the referenced studies mentioned
in previous chapters. Some have tried weighing intraoperative sponges, in combination
with measuring the volume of intraoperative suctioning. Although commonly referenced
as an acceptable measure of blood loss, the influence of fluid evaporation and the
dilutional effect of intraoperative irrigation make this an imprecise measure of
intraoperative red cell mass lost. In a similar light, drain output, with and without
measurement of Hgb values within drain fluid, has been used to measure postoperative
blood loss. These are imprecise measures as drain fluid emanating from the surgical
wound is not the same whole blood lost as a result of surgical trauma. Inflammatory
proteins and extracellular fluid infiltration into the surgical wound during the
postoperative period can significantly influence the actual composition of the drained
fluid. In addition to these biological factors, it is not possible to measure postoperative
drained fluid if no drain is placed intra-operatively, as is common practice at LHSC-UH.
Pioneering work by Nadler and Gross87, 88, and further work by Blecher89, 90, allow
researchers and to calculate the volume of red cell loss based on a comparison of
estimated blood volume (EBV) pre- and postoperatively. This is based predominantly on
hematocrit (Hct), defined as the percentage of whole blood that consists of pRBCs.
Clinically, this is represented as a fraction of 1; for example, a Hct of 0.50 implies that
50% of whole blood is composed of red blood cells. Hematocrit takes into account
dilution and protein composition, enabling calculation of red blood cell mass by
multiplying the Hct with the EBV. The formula used for calculation of blood loss can be
seen in Figure 3.4.
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Figure 3.4: Calculation of Perioperative Blood Loss. All blood loss referenced in the
TeACH-R trial is based on whole blood, assuming Hct of 35 percent. Initial RBC
calculated using the Hct and EBV from the preoperative blood draw closest to the date of
surgery. Final RBC calculated using the lowest measured postoperative Hct. EBV is
based on the most recent height and weight available on the patient’s medical chart.
(Adapted from Rosencher, N et al. Transfusion 2003; 43(4): 459-69)

Calculation of perioperative blood loss was performed for all patients enrolled in the
study. As part of the PAC visit, all study participants had a recent height and weight
available on the chart, enabling calculation of body surface area (BSA; in m2). As part of
the calculation in Figure 3.4, different formulas were used for both men and women, as
per the formula for predicted blood volume in humans derived by Nadler et al88. The Hct
value drawn closest to the operative date was used to calculate the initial RBC. The final
RBC calculation used the lowest measured postoperative Hct level. A volume of 200 mL
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per unit of pRBC transfused was used as standard for compensated RBC loss, when
applicable.

3.6.3 Secondary Outcome Measures
Secondary outcome measures are defined by the investigators as areas of particular
interest relating to, but not directly a part of the primary research question. They are
termed secondary not due to lack of importance, but more because of statistical
implications relating to power calculations. The relevance of findings for secondary
outcome measures is subject to interpretation, as the power of a well-powered RCT is
dependent on the degree of change of the primary outcome. However, important
conclusions can be drawn from a study when clinically and statistically relevant
outcomes are uncovered.

3.6.3.1

Transfusion Rate and Adherence to Transfusion Protocol

The goal of any blood conservation measure is to reduce the need for transfusion. As
part of the TeACH-R protocol, we seek to uncover a difference in the rate of transfusion
between groups. However, the local rate of transfusion after primary THA in 2013,
referring to the number of patients undergoing THA at LHSC-UH needing a minimum
transfusion of 1 unit of pRBC either intra- or postoperatively, is 4.2% (unpublished data).
Powering a clinical trial with this as a primary outcome would require a very large
sample size and heavy cost burden, not possible in this trial given the available funding
opportunities. However, it remains an important outcome measured in this study because
of its clinical applicability. Preoperative autologous blood donation is not considered
part of the perioperative blood conservation protocol at LHSC-UH; a patient would be
excluded from TeACH-R study participation if this treatment modality is part of the
preoperative care plan.

3.6.3.2

Complications

Total hip arthroplasty is considered major orthopaedic surgery, carrying with it the risk of
intra- and postoperative complications. However, when considering the addition of a new
agent to a protocol, it is important to factor in the potential for adverse events as a result
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of the intervention. Table 3.5 describes the complications recorded as part of the
TeACH-R study protocol. These are included in our analysis were selected due to
clinical impact; all listed events require a significant change in treatment protocol,
possibly further surgical intervention. Of particular interest is the incidence of venous
thromboembolic events (VTEs) in the postoperative period, although the investigators
expect a very low incidence given the success of the current thromboprophylactic
regimen. The incidence of intraoperative complications is drawn from the Operative
Report, while postoperative in-hospital complications are noted from clinical progress
notes and the Discharge Summary. As mentioned in 3.5.4, postoperative complications
are tracked up to the 3-month mark postoperatively.
Table 3.5: TeACH-R Recorded Complications.
Intraoperative Complications
Fracture
Acute cardiorespiratory event
Neurologic injury
Vascular injury

Postoperative Complications
Venous thromboembolic event
Skin and soft tissue infection
Deep joint infection requiring revision hip surgery
Acute coronary syndrome
Acute respiratory depression
Acute renal failure
Pneumonia
Acute cerebrovascular accident (stroke) or transient ischemic attack
Wound hematoma
Seizure
Compartment syndrome

3.6.3.3

Inpatient Length of Stay

There are potential benefits associated with a shorter inpatient stay postoperatively,
including a reduced risk of nosocomial infection91, 92 and decreased cost, both important
factors to consider in a publicly funded health care model with limited resources.
Because TeACH-R participants are undergoing an elective procedure requiring admission
to hospital, comparing length of stay against the standard of care is an important metric to
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consider when testing a new intervention that may affect the postoperative course, which
explains its inclusion in the TeACH-R final analysis.

3.7 Statistical Analysis
Appropriate statistical analysis enables the researcher to deduce reasonable conclusions
based on the data collected throughout the course of a study. The TeACH-R trial is a
prospective RCT with the goal of comparing two independent sample populations, meant
to be representative of the population of individuals undergoing primary cementless
THA, for a variety of nominal, ordinal and continuous variables. The samples are
mutually exclusive; a patient can only be enrolled in one treatment arm throughout the
course of the study. Data analysis follows a per protocol design, meaning that participant
data is analyzed based on the treatment a participant receives, not to the treatment arm to
which he or she is allocated to in the event of treatment arm crossover. This is in
comparison to the intention-to-treat protocol commonly used in larger clinical trials,
meant to provide a more conservative assessment of treatment effect. Because both
treatment arms used in this study consist of administering a medication in a single-dose
regimen by the treating surgeon, using the intention-to-treat protocol to decrease the
effect of poor patient compliance is not needed in this study. Therefore, data from a
study participant is analyzed based on the treatment he or she has received
intraoperatively.

3.7.1 Sample Size Calculation
Determining sample size prior to commencement of a study, especially for a randomized
clinical trial with data collected prospectively, is of critical importance. The concept of
statistical power relates to the ability to decrease the chance of making a Type II error,
and is dependent on three factors: sample size, effect size, and level of significance.
Sample size is a major contributor to power in that increasing sample size has the effect
of increasing the probability of detecting a difference in outcome (if one actually exists),
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while maintaining a defined level of significance93. Type II errors, the acceptance of a
false null hypothesis, are unfortunately commonplace in clinical research. Errors in study
methodology, data analysis and the influence of confounding factors can affect the power
of a study. The latter is defined as the ability to detect a difference in outcome if such a
difference actually exists. Best efforts must be made in order to avoid making incorrect
conclusions about a sample population that is either not representative of the target
population, or is not large enough to detect a statistically or clinically significant
difference.
For the TeACH-R trial, the sample size calculation used is shown in Figure 3.5. This is
the sample size calculation for an unpaired, two-tailed t test for two independent sample
populations, based on the primary outcome variable used in this study, ΔHgb. This
statistical test will allow us to identify a difference in the mean ΔHgb in each of our
treatment groups, as well as difference in calculated blood loss. The effect size drives the
sample size calculation. In a previous study from LHSC-UH by Ralley et al,
administration of intravenous TEA prior to the start of THA resulted in a significant
reduction in ΔHgb46. Importantly, the dosing regiment of TEA used in this study is
identical to that used in the TeACH-R trial. Cohen, in his 1988 book, provides a formula
for calculating the d statistic, a measure of effect size assuming normal distribution in the
sample, using the means and standard deviation of continuous variables. Computing the
results from this study into the calculation for Cohen’s results in an effect size of 0.58
(not shown), a moderate effect size93. Assessing effect sizes similar to this, the
investigators determined that performing the sample size calculation with an effect size of
0.52, as presented in Figure 3.5, would allow for a sample size large enough to be able to
detect a clinically meaningful difference between our two treatment groups, while staying
within the allowable margins of unavoidable logistical and financial constraints.
In addition to effect size, other important considerations in interpreting this calculation
include level of significance and power. The level of significance is set at α = 0.05, the
standard for reporting RCTs. There is a then a 5% that the resultant outcome is due to
chance alone, equivalent to a p value less than 0.05 as the determinant of statistical
significance. In a two-tailed analysis, the α level is split between the two ends of the
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normal distribution. We suspect, in theory, that if the topical group were to be different
for the primary outcome of blood loss, it would be more likely deemed inferior to the
intravenous group. However, there is no evidence to support this judgment formed solely
based on lack of experience in using the drug in this fashion. While a one-tailed analysis,
more powerful in nature, would allow us to get away with a smaller sample size, it
implies that we have a clear idea in which direction the test treatment will differ from the
control group. A two-tailed analysis provides a more conservative measure of
assessment, as the TeACH-R investigators do not know in which direction the topical
group will differ from the intravenous group with regards to blood loss. Statistical power
is set at β = 0.80, implying that there is an 80% chance of identifying a difference in
outcomes between our two independent samples, should one actually exist. This is also
the standard for reporting RCTs.

Figure 3.5: TeACH-R Sample Size Calculation. *Effect size of 0.52 determined based
on results of ΔHgb from Ralley, F et al. CORR 2010; 468: 1905-1911.

This study is powered to detect a difference in the primary outcome variable, ΔHgb. To
put it into perspective, an effect size with a standard score of 0.52 is analogous to a ΔHgb
of just over 6 mg/dL. In terms of measured blood loss, this effect size corresponds to
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approximately 300 mL of blood, using the randomized controlled trial by Johansson et al
comparing intravenous TEA to placebo for total blood loss is as the point of reference60.
To the TeACH-R investigators, this magnitude of difference for both variables not only
represents a meaningful statistical difference, but also one that is clinically significant.
Random sampling of 144 participants (or 72 per group) proceeding to THA would allows
us to detect a clinically significant difference, should it exist, for either of our primary
outcome measures. Importantly, the TeACH-R trial is not powered to detect a difference
in any of the secondary outcome measures listed in Section 3.6.3.
The assumption of normal distribution is also important to take into consideration. As a
general rule, a sample size of randomly selected subjects over 30 is deemed to show a
normal distribution for a given variable. The stringent criteria for participant selection, in
addition to the unbiased randomization protocol ensures that, even in this interim
analysis, the sample drawn is representative of the population of interest, where the
dependent primary outcome variables (ΔHgb, calculated blood loss) are assumed to
adhere to the principle of normal distribution.

3.7.2 Outcome Comparison
3.7.2.1

Frequency Data

Not all variables assessed in the TeACH-R trial are measured on a continuous scale.
Frequency data are not amenable to analysis via traditional comparison of means. The
Pearson Chi-Square test is used to compare our two treatment arms when variables are
measured at the nominal level. In essence, it allows the comparison of observed versus
expected frequencies, using the same level of significance of (p < 0.05) as the sample size
calculation above. The Chi-Square analysis, however, mandates an appropriate sample
size for appropriate calculation of the test statistic. If an expected frequency was less
than 5, Fisher’s Exact Test was used to elucidate a potential difference between groups,
again using the same level of significance. This latter test is well known to provide more
appropriate results when smaller samples are compared94.
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3.7.2.2

Comparison of Means

The foundation of the TeACH-R data analysis is in the comparison of means. For this,
we used a two-tailed, unpaired Student’s t test to assess for any between group
differences for all continuous variables. This includes both primary outcome measures.
The Student’s t test provides a mathematically identical result to a one-way analysis of
variance (ANOVA). No variable was identified as having significant influence on the
primary outcome variable; an analysis of covariance (ANCOVA) was therefore not
appropriate for use in this study. The probability level used for comparison is 0.05,
where a significant difference between groups is represented by p < 0.05.

3.7.2.3

Statistical Software

IBM SPSS Statistics, version 22 (IBM Canada Ltd., Markham, Ontario, Canada) was
used to perform all statistical analysis for the TeACH-R study.
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4 Results

4.1 Treatment Arm Allocation
Figure 4.1 displays the results of randomization. At time of interim analysis, 52
participants had completed the initial phase of the TeACH-R protocol, meaning that they
had received the treatment, completed a period of convalescence in hospital, and were
discharged. Thirty-two participants form the current cohort having received intravenous
tranexamic acid, while 20 subjects received the topical regimen intraoperatively.
Drawing attention to key features within Figure 4.1, a relatively high proportion of
screened patients were excluded from TeACH-R study participation (60/120, 50%). The
predominant reason why screened patients were deemed ineligible for study participation
was ineligibility to receive TEA in 21/60 (35%) of potential participants. The most
common reason for not being eligible to receive TEA is a prior diagnosis of DVT or PE
(7/60, 11.6%; data not shown). A diagnosis other than primary OA, RA or AVN
excluded 12 of 60 (20%) of ineligible patients; most commonly, post-traumatic OA was
the primary diagnosis (6/60, 10%; data not shown).
Eight of sixty (13.3%) of enrolled participants withdrew from formal study participation
after being assigned a unique TeACH-R identifier. Data was not collected for these
former participants. Most often, the reason for study exclusion was a problem in
obtaining informed consent prior to the procedure; two enrolled participants withdrew
from the study upon entry into the OR, and in one participant consent was lost
postoperatively. On three occasions, a contraindication to either study participation or
TEA administration altogether was identified only after the patient had consented to
TeACH-R study participation.
Forty-seven of 52 (90.4%) of enrolled TeACH-R participants received the treatment
assigned to them via the process of randomized treatment arm allocation. All five
subjects who received the alternate treatment were slated to receive TEA topically, but
instead were given TEA intravenously prior to the start of the procedure. Interestingly,
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three of these participants were within the first block of 20 randomized participants, with
the other two treatment arm crossovers occurring in the second round of block
randomization, prior to the 40th randomized participant (data not shown). No instances of
treatment arm crossover were recorded in the third block randomization sequence.

Figure 4.1: TeACH-R Treatment Allocation Flow Chart.

4.2 Demographics
Table 4.1 outlines the group comparisons for the listed demographic variables collected
as part of the TeACH-R protocol. At baseline, the two treatment arms are similar for all
variables.
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Table 4.1: Demographic Characteristics for the TeACH-R Trial Sample Population.

Mean Age, years ± SD
Gender, n (%)
Male
Female
THA Laterality, n (%)
Right
Left
Mean Body Mass Index (kg/m2, ± SD)
Mean Body Surface Area (m2, ± SD)
Primary Diagnosis, n (%)
OA
RA
AVN
Mean Charlson Age-Comorbidity Index
Mean ASA Score
Type of Anaesthesia, n (%)
Regional (Spinal)
General
Mean Procedure Time (h:mm, ± SD)
Acetabular Screw Placement, n (%)
Mean Preoperative Hgb, mg/dl ± SD
Preoperative Anemia
Preoperative Hct, ± SD
DVT Prophylaxis, n (%)
Factor Xa Inhibitor
Low Molecular-Weight Heparin

Intravenous
Tranexamic Acid
(n = 32)
63.8 ± 8.7

Topical
Tranexamic Acid
(n = 20)
68.2 ± 9.3

17 (53.1)
15 (46.9)

7 (35.0)
13 (65.0)

18 (56.3)
14 (43.8)
31.2 ± 7.1
2.08 ± 0.31

12 (60)
8 (40)
29.2 ± 6.6
1.98 ± 0.26

31 (96.9)
0
1 (3.1)
3.2 ± 1.4
2.4 ± 0.6

19 (95%)
0
1 (5%)
3.7 ± 1.0
2.3 ± 0.5

23 (71.9)
9 (28.1)
1:08 ± 0:13
7 (21.9)
145.09 ± 12.6
3 (9.4%)
0.432 ± 0.40

17 (85.0)
3 (15.0)
1:10 ± 0:10
4 (20.0)
142.45 ± 11.9
0
0.426 ± 0.36

31 (96.9)
1 (3.1)

20 (100)
0

p value
0.087
0.202

0.790
0.326
0.246

0.732
0.249
0.368
0.274
0.473
0.872
0.457
0.224
0.565
0.425

Important to note in Table 4.1 is the lack of any statistical significant difference between
our two groups with regards to the demographic variables. Almost all participants had a
primary diagnosis of osteoarthritis and received rivaroxaban, a FXa inhibitor, as
thromboembolic prophylaxis for the duration of the postoperative course. However, at
the time of interim analysis, the topical group had a slightly higher proportion of females
than males, the opposite of the intravenous group. This difference did not reach
statistical significance. Although both groups demonstrated similar mean scores on the
Charlson Age-Comorbidity Index, all three participants that were anemic preoperatively
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were allocated to the intravenous TEA group. Although this difference did not meet
statistical significance, it does suggest that the groups have a slight baseline difference in
health status. Despite the presence of these 3 anemic participants in the intravenous
group, the mean preoperative hemoglobin level is not shown to be different between
groups.

4.3 Primary Outcome Measures
4.3.1 Delta-Hemoglobin
Delta-hemoglobin (ΔHgb) is defined as maximal drop in hemoglobin occurring during
the immediate postoperative period. The lowest measured Hgb in hospital is subtracted
from the Hgb value drawn nearest the operative date and time to obtain this measure for
every TeACH-R subject. The mean of all ΔHgb values are compared between patients
receiving intravenous and topical TEA as the primary outcome measure of the TeACH-R
trial.
No significant difference in mean ΔHgb between the intravenous and topical groups was
found (34.81±13.78 mg/dL vs. 35.65±15.54 mg/dL; p = 0.840). Given the wide error
bars, a boxplot was used to identify any outliers that may be acting as confounders. The
boxplot reveals similar features for both treatment groups, with 2 minor outlying values
and 1 major outlying value contributing to the intravenous group.
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Figure 4.2: Postoperative Drop in Hemoglobin (ΔHgb) Following Intravenous and
Topical Tranexamic Acid Administration in Total Hip Arthroplasty. No significant
difference in the means of both treatment groups is identified (A), but boxplot analysis
(B) reveals the presence of minor and major outliers within the treatment arm receiving
intravenous TEA.
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4.3.2 Calculated Blood Loss
Perioperative blood loss was calculated by the method described by Rosencher, as
described in Section 3.6.2.2 and Figure 3.4. Mean blood loss, for all TeACH-R
participants regardless of treatment arm allocation, was 1538 mL. No significance
difference in mean calculated blood loss was identified between the intravenous and
topical TEA treatment arms (1548±509 mL vs. 1521±693 mL; p = 0.873). Significant
variability was noted, given the size of the error bars. Further boxplot analysis does not
identify any significant outliers contributing to this variability.
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Figure 4.3: Calculated Blood Loss Following Intravenous and Topical Tranexamic
Acid Administration in Total Hip Arthroplasty. No significant differences in the
means of both treatment groups (A), although both show significant variability in the
amount of blood lost in the perioperative period (B).

4.4 Secondary Outcome Variables
4.4.1 Length of Stay
Length of stay after THA averaged approximately 55 hours for both groups. There was
no significant difference between those participants having received intravenous vs.
topical TEA (55.0±11.44 vs. 54.5±20.1 hours; p = 0.912).
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Figure 4.4: Length of Stay After Administration of Intravenous and Topical
Tranexamic Acid During Total Hip Arthroplasty.

4.4.2 Transfusion Outcomes
At this time point in the TeACH-R trial, no patient in either group has required a
transfusion of blood products during the postoperative in-hospital stay. Consequently,
there have been no violations in the restrictive transfusion protocol.

4.4.3 Complications
At this point in the process of data analysis, 4 out of 52 (7.7%) TeACH-R study
participants have suffered perioperative complications; 2 were deemed to occur intraoperatively, and 2 in the postoperative period. None of these complications consisted of
VTE. There was no statistical difference in the incidence of perioperative adverse events
between the intravenous and topical TEA treatment arms. One participant having
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received topical TEA had a questionable intraoperative fracture identified on the routine
postoperative radiograph of the pelvis. The weight bearing status of the participant was
changed in the early postoperative period to protect against any component migration or
crack propagation through the floor of the acetabulum. Given the change in management
required as a result of this postoperative finding, this was recorded as a complication.
Subsequently, another patient in the topical group developed a foot drop in the early
postoperative period. A foot drop splint was applied and the patient was discharged with
the diagnosis of sciatic neuropraxia. No further surgical intervention was required. A
third patient in the topical group developed a significant thigh hematoma requiring close
vigilance, but without the need for any additional treatment. The sole complication in the
intravenous group consisted of a deep joint infection requiring urgent irrigation and
debridement.

76

5 General Conclusions and Discussion

Interim analysis of data contained within a large-scale study is an important undertaking
to ensure appropriate study progress. It allows the early identification of possible
deficiencies in data collection, management and analysis, while at the same time giving
some perspective on preliminary outcomes. In an RCT with a well-developed protocol,
where the outcome data is objective and the research team responsible for data collection
and analysis functions independent from the treating physician, minimal bias is
introduced and valuable information can be gained by performing such an interval
assessment of progress.
As the TeACH-R trial approaches the midway point in the recruitment period, promising
results arise from the preliminary analysis. In primary elective total hip arthroplasty
using cementless prosthetic components, the ability to decrease the postoperative
hemoglobin drop (ΔHgb) and reduce surgical blood loss appears similar when topical
TEA is administered by the treating surgeon directly into the joint at the end of the
procedure, compared to the current standard of care of a weight-based dose of TEA
administered intravenously by the attending anaesthesiologist prior to skin incision. In
terms of the secondary outcome measures, no statistically or clinically significant
difference in length of stay or thromboembolic complication rate was identified between
the two treatment groups. Moreover, no transfusion of allogeneic pRBC was required in
either group during the postoperative period. Despite these findings, a conclusion of
therapeutic equivalence or non-inferiority would be erroneous in the setting of
preliminary data analysis, as will be discussed in the following chapter.

5.1 Clinical Relevance
Blood conservation is an important consideration in the care of the arthroplasty patient.
As evidenced in previous chapters, TEA plays an important role the perioperative blood
conservation protocol at LHSC-UH. This study aims to determine whether or not TEA,
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an antifibrinolytic agent, can be administered safely and effectively via the topical route
at the end of THA. Analysis of the available data set shows that topical TEA is, by all
accounts, effective and safe when compared to the current standard of care, intravenous
TEA, in a standard population of patients having THA. Though there is anecdotal
suggestion that administration of the TEA solution makes wound closure slightly more
difficult for the deep muscle and capsule tissue layers during the time solution bathes the
joint area, administering the drug in this manner has significant advantages.
First, topical administration allows direct action on bleeding vessels in tissues around the
hip joint traumatized by aggressive incision, tissue retraction, and osteotomy. During the
surgical approach, best attempts are made to incise through natural tissue planes to get
down to the bone of the proximal femur. However, in trans-muscular approaches such at
the modified direct lateral approach to the hip, incising through muscle is unavoidable,
risking injury to smaller vessels. In the superficial muscular layers of the hip, cautery or
ligation of bleeding vessels is done with relative ease; most of the time, surgical bleeding
from these sources is identified and stopped prior to exposure of the hip joint. More
problematic are the deeper tissues and bony structures of the hip, incised later in the
operation. Surgical incision of capsular tissues around the hip during arthroplasty creates
potential spaces able to accommodate a significant amount of blood loss in anatomic
areas not always visible or accessible to the surgical team. This can result in a significant
amount of unnoticed blood loss during and after hip replacement, in addition to the
relative inability to stop continued blood loss from raw cancellous bone. By
administering topical TEA into the hip joint and surrounding tissues at the end of the
procedure, antifibrinolytic activity can be targeted onto these occult periarticular sources
of bleeding during the postoperative period, without having to be administered
intravenously. As has been shown by the current results of the TeACH-R trial, this
strategy of applying a topical antifibrinolytic appears to be relatively effective, a
promising avenue of treatment.
The second, and arguably more important advantage to topical administration of TEA
relates to the theory that local administration of a drug results in concentrated activity at
the site of application, with decreased levels of systemic absorption compared to the same
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drug administered intravenously. Reliance on diffusion of TEA from the intravascular
compartment to the joint space is less effective than applying the drug directly to the
joint, the source of a significant amount of postoperative bleeding in arthroplasty-related
procedures. It has been determined, in studies where TEA used to counter the fibrinolytic
response after cardiopulmonary bypass, that TEA follows a two-compartment model of
distribution95, 38. In simple terms, diffusion into and elimination from a compartment is
dependent on transfer constants related to the permeability of the tissues and the physical
characteristics of the substance. For the purpose of TEA use in total joint arthroplasty,
this implies an unpredictable concentration of TEA within the operative joint when the
drug is administered intravenously. Administration of the same drug topically means that
the drug is not dependent on diffusion into the joint to be able to exert its action where it
is needed the most, at a concentration that is predictable.
In addition to its effect on blood loss, there is concern that TEA has the ability to stabilize
clots at sites distant to the surgical wound, increasing the risk of thromboembolic events
when used in arthroplasty-related procedures. Thus far in the TeACH-R trial, no
participant has been diagnosed with either a deep vein thrombus or pulmonary embolism,
which is reassuring. Best efforts are made to balance clinical efficacy and systemic load
for TEA, even though robust meta-analysis data has never proven an increased risk of
thromboembolic complications resulting from TEA administration in THA. In addition
to this postulated risk, there has also been suggestion of increased seizure activity when
TEA is administered intravenously at a higher dose, further emphasizing the need for
development of protocols that administer the correct dose for a particular patient, using
the correct route of administration, for fear of causing side effects with administration of
a toxic dose. Though there are few studies that have defined the absorption profile when
TEA in given in THA, we can extrapolate a significant amount of information about the
pharmacokinetic properties of TEA from the aforementioned studies in cardiac surgery,
as well as from the study by Wong et al, who quantified plasma TEA levels after topical
administration of the drug in TKA39. Thanks to these studies, we know there is some
truth for TEA administered locally at the surgical site having significantly less systemic
absorption than the intravenous form of the same drug, and that increasing the dose of a
local TEA does not always parallel the expected clinical benefit. At the very least, our
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results show that at a dose analogous to that used for intra-articular administration in
TKA, clinical efficacy of topical TEA appears to be comparable to that afforded by
intravenous TEA, without an increase in thromboembolic complications. We would
expect the systemic load of TEA of our topical treatment arm to be similar to the 1.5gram intravenous TEA arm of the Wong study, although we do not currently have the
data to support this claim.
Despite these theoretical risks, intravenous TEA remains a valuable adjunct in our
perioperative blood conservation protocol for patients having THA and TKA. At LHSCUH, it is widely regarded as a safe drug when given to the right patient. Since its
inception as standard of care for perioperative blood conservation in lower extremity joint
arthroplasty at LHSC-UH, the influence of intravenous TEA in the arthroplasty patient
population has resulted in improved surgical outcomes, including but not limited to lower
ΔHgb and postoperative transfusion rates, with minimal downside. A large part of this
success is due to the stringent preoperative medical review performed by not only the
surgical team, but also by the clinicians working within the Perioperative Blood
Conservation Program.
An important issue that remains to be determined is precisely who can receive
intravenous TEA, topical TEA, or neither. Interim analysis of the TeACH-R trial has
shown that a significant proportion (35%) of patients having elective primary THA have
a documented contraindication to receiving intravenous TEA as per the TeACH-R
protocol, and are not able to benefit from the drug. It is possible that some of these
patients not eligible for intravenous TEA could benefit from topical TEA, if a decreased
systemic load can be proven with the latter form of treatment. There just simply is not
enough guidance available in the literature to support giving TEA to these patients
deemed to have an elevated risk of adverse events, even though there may not be any
absolute contraindication present within the medical history. Admittedly, given the novel
application of topical TEA in THA for the TeACH-R trial, the exclusion criteria for this
study are decidedly conservative, seeking to enroll participants who fit the medical
profile of the standard arthroplasty patient, without any overt contraindications to TEA
administration. Further investigation into the potential benefit of administering topical
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TEA in a more liberal fashion could be warranted, but this is ultimately dependent on the
final analysis of the TeACH-R trial, which will only be available once the predicted
sample size of 144 participants is achieved.
For the majority of THA patients that can take the drug, weight-based intravenous
administration will likely remain a mainstay of therapy, even with the promising
outcomes that have come in this interim analysis. The single-dose TEA protocol has
been well received by both surgeons and anaesthesiologists alike, not only because of the
significant clinical benefit, but also due to the relative ease of use. The process of formal
adoption of a novel form of therapy is dependent not only on the results of high-quality
RCTs, but also on surgeon preference. However, it will be interesting to re-assess the
results once all data has been collected, in order to determine whether or not these
preliminary outcomes hold true once statistical power is reached for our sample
population. If they do, there may be a role of topical TEA as an alternate to intravenous
TEA for select patients undergoing THA.

5.2 TeACH-R Trial Analysis and Design
Commonly, an RCT seeks to determine superiority over the accepted standard of care
beyond a reasonable doubt. This reasonable doubt, in statistical terms, is the level of
significance. When there is no standard of care, determination of superiority over no
treatment, or placebo, provides the impetus for a change in the standard of care.
Importantly, acceptance of the null hypothesis for a superiority trial is not to be confused
with therapeutic equivalence; after all, as the statistical axiom stipulates, absence of
evidence does not equal evidence of absence.94
In certain circumstances, a form of treatment exists that is widely accepted as the
standard of care for the population under study. If a study participant is eligible to
receive the standard of care, but is assigned to the placebo arm of the study, serious
ethical implications arise due to withholding treatment with known benefit. At LHSCUH, a patient undergoing THA that is able to safely receive TEA intravenously based on
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their preoperative risk profile will receive the drug as standard of care. However, topical
administration of TEA has postulated benefits: decreased systemic absorption and local
action on bleeding vessels are generally desired characteristics of a drug administered to
stop surgical bleeding. The goal of the TeACH-R RCT is to determine whether our test
group, participants receiving topical TEA, show a difference with regards to blood loss
compared to the active agent acting as the standard of care, intravenous TEA.
Initially, the investigators favored a non-inferiority trial design, where the goal is not to
prove superiority, but instead to determine whether topical TEA is inferior to intravenous
TEA with regards to blood loss in THA. However, clinical trials of this variety depend
on the rate of an event occurring, in order to determine the odds ratio of said event
occurring when the novel treatment is given compared to the standard of care. In the end,
we wish to determine the net benefit of the new treatment, defined as the absolute risk
difference. ΔHgb, a continuous measure, is not amenable to determination of risk
reduction. Clinically important event rates for the TeACH-R trial would include the
incidence of postoperative transfusion, or the incidence of thromboembolic phenomena
as a consequence of treatment in either arm. With the advances in patient care that have
come about in the field of orthopaedic surgery, as well as a renewed focus on the medical
care of the orthopaedic patient, these adverse events are a relative rarity. The sample size
required to prove a marginal clinical benefit for these variables is unfortunately beyond
the limits of the available resources for the TeACH-R study.
The ΔHgb and calculated blood loss, on the other hand, provide sensitive parameters to
test our hypothesis, with the requirement of far fewer patients in each of our treatment
arms. Between-group differences in these primary outcome measures also have the
potential to change management, should the results reach clinical significance. In this
interim analysis, we get the initial impression that topical TEA has the potential to be an
efficacious alternative to intravenous TEA for reduction of blood loss in patients having
primary THA, for both aforementioned variables, with little risk of adverse events.
However, caution must be taken in interpreting these interim results, as statistical power
has yet to be achieved for our sample population.

82

5.3 Strengths of the TeACH-R Study
Results emanating from the TeACH-R trial will contribute significantly to understanding
the role and importance of perioperative blood conservation in the arthroplasty patient.
With the gradual increase in use of TEA as a valuable adjunct to perioperative blood
conservation programs, high quality RCTs will become paramount in supporting or
refuting novel therapeutic regimens for TEA. Unfortunately, there are a great number of
clinical trials on the topic, although few are of high-enough quality to effectively change
management. Although a significant number of trials have shown promise when TEA is
given in THA, the variety of treatment protocols makes it difficult to deduce which route
of administration is more effective as an adjunct in controlling perioperative blood loss.
This study will clarify how TEA can be administered most effectively for the patient
having elective primary THA.
The TeACH-R trial is the first and only RCT designed as a direct comparison between
topical and intravenous TEA in THA. There is supportive evidence for using both topical
and intravenous TEA from studies assessing each form of treatment independent of the
other, in placebo-controlled trials, but never have these two treatment alternatives been
compared directly for these primary and secondary outcomes. In the quest to find the
right form of TEA with optimal dosing, comparing all available modalities not only to
placebo, but also to one another is an important step in determining which treatment is
the standard of care for a given population.
Our sample size of 144 participants is powered to detect a clinically significant difference
for two important primary outcomes: the drop in Hgb after hip replacement, and total
blood loss. The assessment of blood loss has traditionally been measured by imperfect
means, and unfortunately these results have permeated the literature surrounding this
topic, often resulting in a significant underestimation of the magnitude of blood loss. The
TeACH-R trial protocol uses a robust formula for calculating blood loss using proven
research methodology to get the most reliable estimate, further increasing the validity of
the treatment comparison. Furthermore, the large sample size helps in decreasing
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variability in our results, and ensures a normal distribution for the continuous variables
studied.
The well-developed prospective study design of this trial also strengthens the validity of
the results by minimizing bias due to errors in study methodology. The stringent
TeACH-R protocol ensures that randomization and blinding are maintained throughout
the duration of the study. In combination with the objective nature of the data collected,
there are few sources of bias even with a single-blinded protocol. The stringent inclusion
and exclusion criteria for the TeACH-R trial isolate the population representative of the
majority of patients proceeding to THA for whom perioperative administration of TEA is
indicated.

5.4 Limitations of the TeACH-R Study
The predominant limitation at this point in time is the size of the available data set. We
have reached a sample size that allows comparison of the means for certain variables
between the treatment arms on the basis of a normal distribution, but have not yet reached
the size necessary to affirm our conclusions. In the end, our current sample is similar to
the target population under study, but the ability to detect a statistically significant
difference in each of our primary outcome variables is limited by the number of
participants in each of our sample group. However, recruitment is proceeding well, and
given that LHSC-UH is a high-volume Canadian center for total joint arthroplasty, it will
not be long before data is available for the final analysis.
The TeACH-R study is not powered to identify any significant difference in any of our
secondary outcome measures, given the infrequent nature of occurrence for these
variables. Even though these outcomes are important, the sample size that would be
required for detect a clinically significant difference for these variable is not possible
given resource limitations.
Another important consideration is that the TeACH-R study does not have a placebo
control group. As mentioned previously, when a treatment exists that is considered
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standard of care, like is the case with intravenous TEA in THA at LHSC-UH, is becomes
unethical to enroll a study subject in a placebo-controlled RCT when he or she would
otherwise be eligible to receive the standard of care. Thankfully, data from the TRANXH trial, published in 2013 with similar study methodology and outcome variables to the
TeACH-R trial, showed that administration of topical TEA was indeed superior to
placebo for blood loss and transfusion rate reduction in THA,56 in addition to the number
of studies that have shown benefit of intravenous TEA in THA for the same outcome
variables. Early in the study development phase, there was consideration for an
additional treatment arm where TEA would be applied earlier in the procedure at time of
arthrotomy, instead of at the end of the procedure when the arthrotomy was closed.
Amongst the arthroplasty surgeons at LHSC-UH that would be participating in this trial,
it was felt that administering TEA at this time, with the mandatory 5-minute pause, would
create an undue surgical delay with minimal perceived benefit. While not considered a
limitation per se, the addition of this treatment arm would have provided relevant data
with regards to timing of topical TEA administration. In all, the comparison between the
two treatment arms in the TeACH-R study represents reliable and valid study
methodology, even without a placebo group.

5.5 Final Remarks and Further Developments
Early in the study development phase, The TeACH-R investigators asked a research
question: is topical TEA, administered directly into the hip joint, as effective at reducing
blood loss compared to intravenous TEA? This simple question led to the development
of a significant research endeavor that has shown significant progress in the twelve
months since its inception.
The purported benefits of topical TEA are not only related to improved control of blood
loss over intravenous TEA, but also on decreasing the potential complications that arise
from administration of intravenous TEA. At the very least, we strive to ensure that this
novel form of treatment is not inferior to the standard of care with regards to blood loss.
At the time of interim analysis, the delivery of TEA topically at the time of arthrotomy
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closure shows similar clinical benefits with regards to perioperative blood loss when
compared to intravenous TEA in THA. Very few adverse events have been identified,
with no difference between the two treatment arms of the TeACH-R trial for all the
variables examined. Should the final analysis show similar findings once the sample size
is large enough for the study to be adequately powered for the primary outcomes of ΔHgb
and calculated blood loss, topical TEA could potentially play a significant role as a
valuable adjunct for perioperative blood management in patients going for THA, in
addition to the current standard of care, intravenous TEA.
Future developments are focused on defining the safety profile of TEA, beginning with
the analysis of plasma TEA levels in patients receiving either topical or intravenous TEA
during THA. This will allow further delineation of safe treatment regimens, and provide
insight into the pharmacokinetic properties of TEA when used at the typical doses for
perioperative blood conservation in THA.
In all, evidence from the interim analysis of the TeACH-R trial, supported by data from
other studies, suggests that TEA administered both intravenously and topically can
provide significant benefit to patients undergoing THA, all the while maintaining a
favorable risk profile. Although much work has yet to be done in uncovering the
intricacies in administering this antifibrinolytic agent safely, exciting opportunities
certainly exist for further development in the field of perioperative blood conservation for
arthroplasty patients. Exploring the clinical efficacy of alternative therapies like these
could usher in a new way of helping the thousands of individuals who proceed to THA
each day in Canada and across the world.
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Appendix A: List of Abbreviations
Apr

Aprotinin

ANOVA

Analysis of variance

ASA

American Society of Anaesthesiologists

BUN

Blood Urea Nitrogen

CBC

Complete blood count

Cr

Creatinine

DDH

Developmental dysplasia of the hip

DTI

Direct thrombin inhibitor

DVT

Deep vein thrombosis

ΕACA

Epsilon-aminocaproic acid

ESA

Erythropoietin-stimulating agent

FVII(a)

Factor VII (activated)

FX(a)

Factor X (activated)

FXaI

Factor Xa inhibitor

FXIII(a)

Factor XIII (activated)

Hct

Hematocrit

Hgb

Hemoglobin

IA

Intra-articular

INR

International Normalized Ratio
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IT

Ilio-tibial

IV

Intravenous

LCPD

Legg-Calvé-Perthes disease

LHSC-UH

London Health Sciences Centre, University Hospital

LMWH

Low-molecular-weight heparin

OA

Osteoarthritis

ONP

Orthopaedic Nurse Practitioner

OR

Operating Room

PAC

Pre-Admission Clinic

PBCP

Perioperative Blood Conservation Program

PE

Pulmonary embolus

pRBC

Packed red blood cells

PTT

Partial thromboplastin time

RA

Rheumatoid arthritis

RCT

Randomized controlled trial

SCFE

Slipped capital femoral epiphysis

TEA

Tranexamic acid

TeACH-R

Tranexamic Acid Comparison in Hip Replacement (Trial)

TF

Tissue Factor
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THA

Total hip arthroplasty

TKA

Total knee arthroplasty

UFH

Unfractionated heparin

VTE

Venous thromboembolic event
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Appendix C: TeACH-R Consent Form
Comparative Efficacy of Topical versus Intravenous Administration of
Tranexamic Acid in Primary Total Hip Arthroplasty
Study Doctors
Dr. Douglas Naudie – London Health Science Centre
Dr. James Howard – London Health Science Center
Dr. Fiona Ralley – London Health Sciences Centre
Dr. Lyndsay Somerville – Sandy Kirkley Centre for Musculoskeletal Research
Dr. Richard Nadeau – Orthopaedic Surgery Resident
Study Coordinators
Katherine Hrabok
Abigail Korczak
Dear Patient:
You are being invited to voluntarily participate in a research study designed for patients
undergoing a total hip replacement. This letter of information describes the research
study and your role as a participant. Please read this letter carefully. Do not hesitate to
ask anything about the information provided. Your doctor or nurse will describe the study
and answer your questions.
Purpose
The rationale for this project focuses on preventing bleeding in total hip replacement
surgery. The ability to stop bleeding is of concern to the surgeon, as joint replacement
carries a high risk of complications when significant bleeding happens. Albeit necessary
at times, and generally deemed safe, your surgical team is looking to decrease the rate of
transfusion of blood products after your hip replacement.
Tranexamic acid is a drug that has received lots of attention recently, as it helps to reduce
post-operative bleeding. In total knee replacement, a tourniquet around the leg can be
used to control bleeding; this is not possible when your surgeon is operating on your hip.
Currently at LHSC, tranexamic acid is administered in its intravenous (IV) form to most
patients undergoing joint replacement. Your anaesthetist would give you this drug prior
to the start of the operation. This same drug placed directly into the joint (termed
‘topical’ administration) at the end of the procedure may also be beneficial; giving it this
way allows for direct action of the drug on sites of bleeding. Compared to the IV route,
there is less of the drug absorbed throughout the rest of the body. To date, no studies
have directly compared IV versus topical administration of tranexamic acid in hip
replacement surgery in terms of either safety or effectiveness.
This study is designed to compare the two methods of administering tranexamic acid in
patients who receive a total hip replacement. The two groups studied are as follows:
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1. One group will receive the intravenous form of tranexamic acid, administered
prior to the start of the procedure. This is the standard protocol for joint
replacement at University Hospital.
2. The second group will receive the topical form of tranexamic acid, to be
infiltrated as a sterile solution directly into the hip joint once the implants are
secured into the bone. It will be kept in for 5 minutes while your orthopaedic
surgeon finishes the operation.
In order to provide further insight into the absorption of tranexamic acid, we will also
collect one additional blood sample within one hour of administration of the drug, in both
groups, to measure levels of tranexamic acid in the blood stream. All other blood
samples will be drawn as per the standard hip replacement pathway. The investigators
will collect data indicative of post-operative bleeding and any complication that arises
during your stay in hospital.
The results from this study may help researchers improve blood conservation strategies
for hip replacement surgery in the future. The main purpose of this study is to determine
which route of administration provides the safest and most effective way of delivering
tranexamic acid during hip surgery. If no difference is seen, the current standard of care,
which is to administer the drug intravenously prior to the procedure, will continue to be
utilized.
Approximately 144 patients from London Health Sciences Centre will participate.
Procedure
Should you meet the study criteria and wish to participate, you will be randomly
assigned, like a flip of a coin, to one of the two groups. You will not know what group
you are in. All patients will continue to receive the same level of care in the time leading
up to, during, and after surgery.
Either during surgery, or while you are recovering from surgery, a health care
professional will collect a blood sample to be sent for tranexamic levels.
After your surgery, the investigators will monitor your progress in hospital by reviewing
your medical chart. Only data relevant to the study will be collected from your chart. A
de-identification process ensures that only the study investigators will be able to link the
health information contained in the chart with your personal information. The care
providers that follow your progress after hip surgery will not be aware which study group
you are in, and will not be able to answer questions related to the study. There will be no
information present within your chart that tells the nurses and allied care professionals for
of the drug you have received. However, the surgeon and residents caring for you while
in hospital may be aware of which group you are randomized to, and are given strict
instruction not to discuss the study or divulge any study-related information. They will
determine whether you will need a blood transfusion, and will manage any medical issues
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that arise while you are in hospital. There will be no difference in your hip replacement,
physiotherapy or nursing care after surgery.
Study Risks
By participating in this study, you are at no increased risk compared to current standard
of care in total hip replacement surgery.
As your medical chart will be reviewed, an infringement on your privacy may occur.
Your individual results will be held in confidence. No person, other than your doctor,
nurses and the study team will have access to your study-related records without your
permission.
During the course of the study you will be informed of any significant new finding (either
good or bad), such as changes in the risks or benefits resulting from participation in the
study or new alternatives to participations that might change your decision to continue
participating in this study. If new information is provided to you, your written consent to
continue participating in this study will be requested.
Study Benefits
You may or may not benefit directly from participation in this study. The results of this
study may be of benefit by helping surgeons discover new ways to reduce blood loss
during hip surgery.
Voluntary Participation
Participation in the study is voluntary. You may refuse to participate, refuse to answer
any questions or withdraw from the study at anytime with no effect on your future care.
You do not waive any legal right
by signing the consent form. There is a process of de-identifying your personal health
information from the data collected in the study. Be aware that once data has been deidentified it will become impossible to have your data withdrawn from the study.
Alternatives to Study Participation
You will receive standard medical care by your doctor if you choose not to participate in
this study. If you decide not to participate in this study, your surgeon and
anaesthesiologist will determine whether or not you will receive tranexamic acid during
your surgery. You do not have to participate in this study in order to have your hip
replacement surgery.
Confidentiality
You will not be identified personally in any publication or communication resulting from
this study. All
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information collected will be stored in a locked office and entered into a secure database,
accessible by authorized individuals only. Your identifiable information, such as your
name, hospital identification number and surgery date, will be held separately from the
other information collected and will be only linked by a study ID number. This
information will be used solely for the advancement of medical science and any personal
information will be kept confidential. A copy of this letter will be given to you.
Representatives of the University of Western Ontario Health Sciences Research Ethics
Board may
contact you or require access to your study-related records to monitor the conduct of the
research.
If you have any questions about your rights as a research participant or the conduct of the
study you may contact Dr. David Hill, Scientific Director, Lawson Health Research
Institute 519-667-6649.
If you have any questions about this study or your care please contact Katherine Hrabok,
Clinical Research Coordinator, Department of Orthopaedics, London Health Sciences
Center – University Hospital, or Dr. Jamie Howard, primary study investigator and
Orthopaedic Surgeon at London Health Sciences Center.
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Comparative Efficacy of Topical versus Intravenous Administration of
Tranexamic Acid in Primary Total Hip Arthroplasty
Informed Patient Consent
Agreement of Participating Subject
I have read the letter of information, have had the nature of the study explained to me,
and I agree to participate. All questions have been answered to my satisfaction.

Print Participant’s full name

Participant’s signature

Date

Name of person obtaining consent

Signature of person obtaining consent

Date

103

Appendix D: Medical Directive for Tranexamic Acid
SRG-2010-003

Medical Directive

Preoperative Written Order for Tranexamic Acid (TA) in

Title:

Orthopedic Surgery

Lead Contact Person:

Donna Berta, PBCP Coordinator

Program:

Surgery / Anesthesia and Perioperative Medicine

Approval By:

Medical Advisory Committee

Original Effective

Revised Date:

Reviewed Date:

Date:
This Medical Directive Applies to:
LHSC-UH

LHSC-VH

All LHSC sites or
LHSC-SSH

Order:
Knee surgery:
Send to Surgical Prep Unit
Tranexamic acid * mg (wt ** kg), in 50 mL 0.9 % sodium chloride IV, administer at
patellar clamping
v/o Dr. F. Ralley/_____ PBCP RN
Hip surgery:
Send to Surgical Prep Unit
Tranexamic acid * mg (wt **kg), in 50 mL 0.9 % sodium chloride IV, administer 10
minutes prior to
skin incision
v/o Dr. F. Ralley/_____ PBCP RN
* dose of TA based on table Tranexamic Acid order per Patient Weight Increment (see
Appendix 2)
** patient’s weight measured at Preadmission Clinic assessment or estimate if patient
unable to weight
bear

104

Appendix Attached?

Yes

No

Recipient Patients:
University Hospital Orthopedic Surgery patients of Drs. Bourne, Howard, MacDonald,
McAuley, McCalden, and Naudie assessed via Preadmission Clinic undergoing elective
surgical procedures
• unicompartmental, primary, bilateral, revision knee joint replacement
• primary, bilateral, revision hip joint replacement
• periacetabular and femoral osteotomy and open surgical dislocation hip surgery
Authorized Implementers:
Position / Title
Registered Nurse

Qualifications / Certifications
RN in the Blood Conservation
Program

Indications & Contraindications:
Indications:
1. All University Hospital Orthopedic Surgery patients assessed via Preadmission Clinic
undergoing elective surgical procedures (procedures as listed Recipient Patients)
provided the patient has absolutely no history of previous thrombotic vascular event
(TVE)
2. For University Hospital Orthopedic Surgery patients assessed via Preadmission Clinic
undergoing elective orthopedic surgical procedures not listed in Recipient Patients, if
the PBCP nurse believes TA might be indicated, she may contact the attending
Orthopedic Surgeon for direction regarding potential implementation of intra-operative
TA
Relative Contraindications:
1. The PBCP Nurse will consult the PBCP Director or their designate regarding patients
with history of TVE. The PBCP Director or designate will review such patients to assess
the patient specific risk/benefit profile and advise the PBCP nurse if TA is to be ordered
or not.
2. The PBCP Nurse will consult the PBCP Director or their designate regarding patients
with drug eluting stents to treat coronary artery disease within the previous 2 years and
ongoing Plavix treatment. The PBCP Director or designate will review such patients to
assess the patient specific risk/benefit profile and advise the PBCP nurse if TA is to be
ordered or not.

•

Absolute Contraindications:
1. Patients with history of TVE in previous 12 months or requiring life long
anticoagulation related to previous TVE
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Medication / Drug Table:
Drug
Name
(GENERIC
only)

Route of
Administration
& Dosage
Range

Indication

Absolute
Contraindications

Tranexamic
Acid

Intravenous in
50 mL 0.9 %
sodium chloride
minibag
See Appendix 2
regarding
dosage range
Administered
intraoperatively
by Attending
Anesthesiologist

To
decrease
surgical
blood loss
in
orthopedic
knee and
hip joint
surgery

Patients with
history of TVE in
previous 12
months or
requiring life long
anticoagulation
related to previous
TVE

Considerations
for Dosage
adjustment
(e.g. Renal or
hepatic)
none

Special
Monitoring
Requirements
(i.e. lab tests)
none

Reference:
1. Compendium of Pharmaceuticals and Specialties. Canadian Pharmacists Association,
Ottawa 2007:
Cyklokapron, 649.
2. LHSC intranet Parenteral Drug Administration Manual
http://www.lhsc.on.ca/priv/monograph/Of8olI6eAhQAABlCTNE.htm
Consent:
• Attending Orthopedic Surgeon who obtains the surgical procedure consent, also
obtains consent for blood and blood products and any alternatives (Form #84605645 revised 2008)
Educational Requirements
Information or educational requirements to guide practice include:
• Minimum of 5 years recent clinical experience in surgical patient care
• Completion of ONTraC blood conservation orientation program
• Ongoing participation in ONTraC program continuing education
Appendix attached?

Yes

No

Documentation & Communication:
• PBCP assessment, consultation with PBCP Director or their designate, plan of care
and treatment implemented is documented on the patient’s Health Record utilizing
Perioperative Blood Conservation Program form (NSR5080 revised 2009).
• Written order for TA is documented on the LHSC Patient Care Order form (84605602 revised 2009)
Review and Quality Monitoring Guideline:
• For this Medical Directive TVE is defined as: stroke, transient ischemic attack, deep
vein thrombosis, pulmonary embolism
• The PBCP director or their designate will be contacted via email (as per LHSC
Electronic Mail Use Policy INT 006) regarding patients with history of TVE. The
PBCP Director or designate will review such patients to assess the patient specific
risk/benefit profile and will reply by email to advise the PBCP nurse if TA is to be
ordered or not.
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•

•

In situations of limited pre-operative time frame, telephone communication will occur
All University Hospital Orthopedic Surgeons track their own patient TVE incidents;
frequency of TVE incidents is reviewed semi-annually at Orthopedic Surgeons
Division meeting. Dr. D. Naudie, Orthopedic Surgeon and PBCP Committee
member will advise PBCP Director or their designate of any increase in frequency of
such incidents
Blood transfusion rates for University Hospital Orthopedic Surgery procedures are
reported semi annually to the PBCP Director and to Orthopedic Surgeons by Donna
Berta, PBCP Coordinator

Professional Staff Approvals (Physician, Dentist, Midwife):
• Identify all Professional Staff members (<10 list by individual name, >10 list by
title & program) responsible for patients who may receive an order or
procedure under this medical directive.
NAME

DEPARTMENT / PROGRAM

Dr. Fiona Ralley

Director, PBCP

Dr. Ian Chin-Yee

Hematologist, PBCP

Dr. Cyrus Hsia

Hematologist, PBCP
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SRG-2010-003

Administrative Authorization Approval Form
Please note: signature pages are not to be signed until the medical directive has
been approved.
Medical Directive:

Preoperative Written Order for Tranexamic Acid (TA) in
Orthopedic Surgery

Lead Contact Person (s):

Donna Berta, PBCP Coordinator

Administrative Authorizations
(approved by):
Chair, LHSC Medical Advisory
Committee / Dr. Christopher
Fernandes
Chair, Drug & Therapeutics
Committee / Dr. David Massel
Director, Perioperative Blood
Conservation Program / Dr.
Fiona Ralley
Hematologist, Perioperative
Blood Conservation Program /
Dr. Ian Chin-Yee
City-Wide Chair-Chief
Anesthesia & Perioperative
Medicine / Dr. Davy Cheng
Anesthesia Site Chief –
University Hospital / Dr. Chris
Harle
Orthopedic Surgery Division
Chief / Dr. James Roth
Surgery Site Chief – University
Hospital / Dr. Steven J.
MacDonald
Director, Surgical Care Program
/ Ms. Carol Rhiger

Signature

Date

108

Nursing Professional Practice /
Kathleen Ledoux, or delegate
Implemented by:
(Person(s) performing
initiation or person
representing a large group and
responsible for notification of
that group)
Donna Berta, PBCP Coordinator
Valerie Binns, PBC Coordinator

Signature

Date
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